

# CITATION REPORT

List of articles citing

## Recommendations of the Panel on Cost-Effectiveness in Health and Medicine

DOI: 10.1001/jama.1996.03540150055031

JAMA - Journal of the American Medical Association,  
1996, 276, 1253.

**Source:** <https://exaly.com/paper-pdf/27558966/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1612	Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. <b>1997</b> , 10, 413-21		12
1611	Assessing the effectiveness of follow-up care for colorectal cancer: a great conceptual and methodological challenge for clinical oncology. <b>1997</b> , 8, 1059-62		3
1610	Avoiding double-counting in pharmacoeconomic studies. <b>1997</b> , 11, 385-8		43
1609	International comparisons of critical care outcome and resource consumption. <b>1997</b> , 13, 389-407		56
1608	Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee. <b>1997</b> , 8, 137-49		94
1607	The generalisability of pharmacoeconomic studies. <b>1997</b> , 11, 503-14		32
1606	Understanding the term "cost-effectiveness". <b>1997</b> , 9, 603-4		4
1605	Theoretical issues in cost-effectiveness analysis. <b>1997</b> , 16, 121-8		71
1604	Assessing Outcomes in Population Health: Moving the Field Forward. <b>1997</b> , 13, 3-5		14
1603	A summary of economic evaluations published in the field of rheumatology and related disciplines. <b>1997</b> , 40, 1587-93		20
1602	Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. <b>1997</b> , 80, 1052-64		52
1601	Cost-effectiveness analysis and nursing research--is there a fit?. <b>1998</b> , 30, 221-2		5
1600	Milton Weinstein's insights on the development, use, and methodologic problems in cost-effectiveness analysis. <b>1998</b> , 30, 223-7		1
1599	Methods for conducting and reporting cost-effectiveness analysis in nursing. <b>1998</b> , 30, 229-34		6
1598	Cost-effectiveness analysis in the nursing literature, 1992-1996. <b>1998</b> , 30, 235-42		11
1597	Health services research clinical trials: issues in the evaluation of economic costs and benefits. <b>1998</b> , 19, 149-58		12
1596	The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance. <b>1998</b> , 179, 411-20		15

1595	What to consider when conducting a cost-effectiveness analysis in a clinical setting. <b>1998</b> , 98, 1149-54	6
1594	Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. <b>1998</b> , 82, 2235-40	49
1593	The effectiveness of cost-effectiveness analysis in containing costs. <b>1998</b> , 13, 664-9	84
1592	Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate. <b>1998</b> , 40, 593-603	10
1591	Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer. Gynecology Tumor Group. <b>1998</b> , 42, 87-90	14
1590	Outcomes research in your office. <b>1998</b> , 38, 987-9	3
1589	Management of perioperative pain in hospitalized patients: a national survey. <b>1998</b> , 10, 77-85	54
1588	The economics of febrile neutropenia: implications for the use of colony-stimulating factors. <b>1998</b> , 34, 1857-64	163
1587	Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. <b>1998</b> , 114, 893-901	40
1586	Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. <b>1998</b> , 31, 1490-2	5
1585	Prenatal screening for cystic fibrosis carriers: an economic evaluation. <b>1998</b> , 63, 1160-74	58
1584	Principles of disease management in neonatology. <b>1998</b> , 45, 651-72	2
1583	Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings. <b>1998</b> , 14 Suppl 2, 11-23	7
1582	Evidence-based medicine and cost-effectiveness analysis. <b>1998</b> , 14, 525-37	12
1581	The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. <b>1998</b> , 14, 49-58	11
1580	Cardiac rehabilitation in the elderly. <b>1998</b> , 10, 273-83	1
1579	Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. <b>1998</b> , 52, 586-94	9
1578	Tests of preferential independence in the QALY model. <b>1998</b> , 18, 418-28	18

1577	A proposal for structured abstracts of health economic studies. <b>1998</b> , 32, 1244-6	2
1576	Evaluating and Regulating Pharmacoeconomic Information in the Private Sector. <b>1998</b> , 32, 525-532	
1575	Drug therapy: the impact of managed care. <b>1998</b> , 44, 1-32	
1574	Book Reviews. <b>1998</b> , 18, 240-244	2
1573	A systematic review of the cost-effectiveness of noncardiac transitional care units. <b>1998</b> , 113, 172-7	55
1572	A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. <b>1998</b> , 88, 61-7	20
1571	Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel. <b>1998</b> , 14, 505-13	41
1570	Health economics in the treatment of colorectal cancer. <b>1998</b> , 16, 582-7	1
1569	Statistical Analysis of Total Labor Pain Using the Visual Analog Scale and Application to Studies of Analgesic Effectiveness During Childbirth. <b>1998</b> , 87, 723-727	45
1568	Medical Technology Assessment. <b>1998</b> , 87, 1271-1282	5
1567	Statistical analysis of total labor pain using the visual analog scale and application to studies of analgesic effectiveness during childbirth. <b>1998</b> , 87, 723-7	129
1566	Medical technology assessment: an overview. <b>1998</b> , 87, 1271-82	28
1565	Economic Aspects of the Perinatal Hospital Stay. <b>1998</b> , 25, 483-498	6
1564	Paying the piper for pharmacoeconomic studies. <b>1998</b> , 18, S23-6	6
1563	Cost-Effectiveness Analysis in Pathology. <b>1999</b> , 19, 757-771	8
1562	Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. <b>1999</b> , 16, 499-520	32
1561	Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. <b>1999</b> , 160, 358-67	156
1560	The effect of acute respiratory distress syndrome on long-term survival. <b>1999</b> , 160, 1838-42	82

1559	Cost-effectiveness of regulations against using a cellular telephone while driving. <b>1999</b> , 19, 1-8	31
1558	Quality of life and economic evaluation in SLE clinical trials. <b>1999</b> , 8, 645-54	34
1557	Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Canadian Collaborative Cardiac Assessment Group. <b>1999</b> , 19, 149-56	17
1556	Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. <b>1999</b> , 212, 117-25	248
1555	Assessing the cost-effectiveness of postmastectomy radiation therapy. <b>1999</b> , 44, 91-8	24
1554	Estimating the cost of medical care. <b>1999</b> , 34, 535-7	2
1553	Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies. <b>1999</b> , 2, 78-81	26
1552	Panel 5: application of healthcare intervention economic evaluations in healthcare decision-making. <b>1999</b> , 2, 92-8	2
1551	Resources Used by Panelists. <b>1999</b> , 2, 107-112	
1550	Towards a European consensus on conducting and reporting health economic evaluations--a report from the ISPOR Inaugural European Conference. <b>1999</b> , 2, 281-7	8
1549	What outcomes matter to patients?. <b>1999</b> , 14, 357-63	60
1548	Cost-effectiveness of the diagnostic evaluation of vertigo. <b>1999</b> , 109, 600-5	41
1547	Economic evaluation of cancer treatments: a review of the methods. <b>1999</b> , 11, 78-83	4
1546	[Common effect measures in medical and health economics studies? Results of an exploratory survey of physicians]. <b>1999</b> , 94, 665-72	1
1545	Covariation of physical and mental symptoms across illnesses: results of a factor analytic study. <b>1999</b> , 21, 122-7	8
1544	Intensive antihypertensive treatment to the new lower blood pressure targets. <b>1999</b> , 1, 313-9	2
1543	Using disease-state management as the key to promoting employer sponsorship of medical nutrition therapy (continuing education credit). <b>1999</b> , 99, 583-8; quiz 589-90	3
1542	Is the use of radiation therapy after mastectomy cost-effective?. <b>1999</b> , 9, 287-91	2

1541	Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. <b>1999</b> , 29, 21-6	42
1540	Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. <b>1999</b> , 30, 1077-81	41
1539	Economic consequences of the progression of rheumatoid arthritis in Sweden. <b>1999</b> , 42, 347-56	139
1538	Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. <b>1999</b> , 2, 91-92	33
1537	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. <b>1999</b> , 2, 111-121	19
1536	Costs and Benefits of Prevention and Disease Management. <b>1999</b> , 5, 153-166	20
1535	Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. <b>1999</b> , 19, 371-7	82
1534	Using healthcare claims data for outcomes research and pharmacoeconomic analyses. <b>1999</b> , 16, 1-8	78
1533	Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci. <b>1999</b> , 16, 153-63	21
1532	Open versus endoscopic carpal tunnel release: a decision analysis. <b>1999</b> , 24, 1109-17	43
1531	Cost-comparison analysis versus cost-effectiveness analysis: An important difference. <b>1999</b> , 41, 1050	5
1530	A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. <b>1999</b> , 126, 568-576	18
1529	Cost-effectiveness of substance abuse services. Implications for public policy. <b>1999</b> , 22, 385-400, x	13
1528	Costing vascular surgery: A review of current reporting practice. <b>1999</b> , 30, 668-78	2
1527	Cost-effectiveness of stress-echocardiography. <b>1999</b> , 17, 583-95, x	1
1526	Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. <b>1999</b> , 138, 376-83	51
1525	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. <b>1999</b> , 137, S41-6	10
1524	Finding answers to questions using cost analysis. <b>1999</b> , 70, 128-30	2

1523	Statistical Analysis of Total Labor Pain Using the Visual Analog Scale and Application to Studies of Analgesic Effectiveness During Childbirth. <b>1999</b> , 88, 1194	
1522	Statistical Analysis of Total Labor Pain Using the Visual Analog Scale and Application to Studies of Analgesic Effectiveness During Childbirth. <b>1999</b> , 88, 1194	
1521	Lifetime health and economic benefits of weight loss among obese persons. <b>1999</b> , 89, 1536-42	117
1520	Evaluation of costs in rheumatic diseases: a literature review. <b>1999</b> , 11, 104-9	17
1519	Is the societal perspective in cost-effectiveness analysis useful for decision makers?. <b>1999</b> , 25, 447-54	22
1518	Systematic overview of cost-utility assessments in oncology. <b>2000</b> , 18, 3302-17	253
1517	Estimating the benefits of solitary pancreas transplantation in nonuremic patients with type 1 diabetes mellitus: a theoretical analysis. <b>2000</b> , 70, 1121-7	28
1516	Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. <b>2000</b> , 232, 763-76	45
1515	A trial for comparing methods for eliciting treatment preferences from men with advanced prostate cancer: results from the initial visit. <b>2000</b> , 38, 1040-50	38
1514	Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. <b>2000</b> , 11, 157-61	28
1513	Measuring quality of life in epilepsy surgery patients. <b>2000</b> , 27 Suppl 1, S111-5; discussion S121-5	8
1512	Quality of life in survivors of colorectal carcinoma. <b>2000</b> , 88, 1294-1303	233
1511	Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. <b>2000</b> , 15, 439-45	30
1510	The cost of hepatitis A infections in American adolescents and adults in 1997. <b>2000</b> , 31, 469-73	122
1509	Estimates of the lifetime direct costs of treatment for metastatic breast cancer. <b>2000</b> , 3, 23-30	40
1508	A comparison of two methods for estimating the technical costs of external beam radiation therapy. <b>2000</b> , 47, 461-7	20
1507	Cost effectiveness analysis of school based Mantoux screening for TB infection. <b>2000</b> , 24, 247-53	5
1506	Economic aspects of peripheral arterial disease. <b>2000</b> , 19, S39-S46	

1505	Cost-effectiveness of stress echocardiography and nuclear perfusion imaging. <b>2000</b> , 43, 197-214	1
1504	Economic evaluation of alcohol treatment services. <b>2000</b> , 23, 27-39	38
1503	Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). <b>2000</b> , 86, 747-52	31
1502	Assessing the cost-effectiveness of pharmacogenomics. <b>2000</b> , 2, E29	108
1501	Cost effectiveness of vaccinating food service workers against hepatitis A infection. <b>2000</b> , 63, 768-74	22
1500	Assessing the quality of economic evaluations of health care interventions. <b>2000</b> , 11, 1513-5	2
1499	Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. <b>2000</b> , 11, 1591-5	32
1498	Survival gain in cost-effectiveness studies. <b>2000</b> , 18, 3318	3
1497	Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?. <b>2000</b> , 102, 722-7	58
1496	Are pharmaceuticals cost-effective? A review of the evidence. <b>2000</b> , 19, 92-109	125
1495	A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. <b>2000</b> , 20, 413-22	84
1494	The cost effectiveness of anesthesia workforce models: a simulation approach using decision-analysis modeling. <b>2000</b> , 90, 584-92	24
1493	Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. <b>2000</b> , 117, 875-80	41
1492	Priority-setting in New Zealand: translating principles into practice. <b>2000</b> , 5, 170-5	12
1491	Economic evaluation of infection control practices in day care and the home: methodologic challenges and proposed solutions. <b>2000</b> , 19, S125-8	5
1490	Cost-effectiveness of orthoptic screening in kindergarten: A decision-analytic model. <b>2000</b> , 8, 79-90	8
1489	Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. <b>2000</b> , 106, 520-6	131
1488	A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. <b>2000</b> , 20, 451-67	133



1487	Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. <b>2000</b> , 31, 444-50	107
1486	On the economic foundations of CEA. Ladies and gentlemen, take your positions!. <b>2000</b> , 19, 439-59	84
1485	Economic analysis of complementary medicine: a systematic review. <b>2000</b> , 8, 111-8	60
1484	Estimates of the lifetime costs of breast cancer treatment in Canada. <b>2000</b> , 36, 724-35	113
1483	Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. <b>2000</b> , 19, 15-23	73
1482	Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. <b>2000</b> , 17, 339-49	69
1481	Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. <b>2000</b> , 17, 603-9	11
1480	Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. <b>2000</b> , 18, 261-8	3
1479	Health economics of contraception. <b>2000</b> , 27, 917-31, viii	5
1478	Economic aspects of peripheral arterial disease. <b>2000</b> , 31, S45-S53	
1477	COSTBENEFIT ANALYSIS FOR ALLERGEN IMMUNOTHERAPY. <b>2000</b> , 20, 593-607	3
1476	Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators. <b>2000</b> , 106, 995-1018	17
1475	Economics of lower urinary tract symptoms (LUTS) in older people. <b>2001</b> , 18, 213-23	11
1474	Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. <b>2001</b> , 33, 639-45	20
1473	Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. <b>2001</b> , 111, 130-9	57
1472	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. <b>2001</b> , 111, 633-42	127
1471	Accuracy of terminology and methodology in economic analyses in otolaryngology. <b>2001</b> , 124, 496-502	19
1470	The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. <b>2001</b> , 19, 3076-90	144

1469	Decision analysis and its application in clinical medicine. <b>2001</b> , 94, 172-9	11
1468	Analysis of pharmacoeconomics of sedation and analgesia. <b>2001</b> , 17, 1003-13, x	33
1467	The effectiveness of a home visit to prevent childhood injury. <b>2001</b> , 108, 382-8	80
1466	Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS. <b>2001</b> , 1, 77-84	4
1465	Economic evaluations of adult pneumococcal vaccination strategies. <b>2001</b> , 1, 47-58	11
1464	Quality-adjusted survival in the first year after the acute respiratory distress syndrome. <b>2001</b> , 163, 1389-94	270
1463	Cost-Effectiveness Analyses: A Basic Overview for Dermatologists. <b>2001</b> , 5, 217-222	1
1462	Patient preference for cancer therapy: an overview of measurement approaches. <b>2001</b> , 19, 220-30	137
1461	Economics of end-of-life care in the intensive care unit. <b>2001</b> , 29, N46-51	52
1460	Cost Analysis for Pathologic Evaluation of Metastatic Carcinoma of Unknown Origin. <b>2001</b> , 6, 173-177	3
1459	Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. <b>2001</b> , 29, 1659-65	37
1458	Cost Identification Analysis for Succinylcholine. <b>2001</b> , 92, 693-699	13
1457	Cost identification analysis for succinylcholine. <b>2001</b> , 92, 693-9	3
1456	Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia : potential economic implications. <b>2001</b> , 119, 228-35	163
1455	Pharmacogenomic testing: the cost factor. <b>2001</b> , 1, 171-4	28
1454	Cost analysis of vaginal birth after cesarean. <b>2001</b> , 44, 571-87	5
1453	Treatment Options for Diabetic Neuropathic Foot Ulcers. <b>2001</b> , 27, 347-351	2
1452	Economics, quality of life and breast cancer outcomes ¶Is a balance possible?. <b>2001</b> , 10, 190-198	

1451	Getting closer to the truth: overcoming research challenges when estimating the financial impact of worksite health promotion programs. <b>2001</b> , 15, 289-95	19
1450	Locally advanced head and neck cancer. <b>2001</b> , 2, 7-13	14
1449	Economic analysis of randomized, controlled trials. <b>2001</b> , 3, 396-403	5
1448	Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. <b>2001</b> , 50, 979-89	10
1447	De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. <b>2001</b> , 91, 928-939	40
1446	Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). <b>2001</b> , 10, 751-74	86
1445	Newborn mass screening versus selective investigation: benefits and costs. <b>2001</b> , 24, 299-302	6
1444	Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis. <b>2001</b> , 16, 701-11	33
1443	An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness. <b>2001</b> , 25, 222-9	18
1442	Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. <b>2001</b> , 87, 984-8; A4	79
1441	[Analysis of the medico-economic literature comparing primary angioplasty and thrombolysis in the management of acute myocardial infarction]. <b>2001</b> , 50, 330-9	
1440	Understanding economic analyses. <b>2001</b> , 2, 2-5	7
1439	Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. <b>2001</b> , 32, 419-30	144
1438	Cost Comparison of Immunohistochemical Tests in a Veterinary Diagnostic Laboratory: Experience With 78 Antibodies. <b>2001</b> , 24, 17-21	1
1437	The costs of caring: medical costs of Alzheimer's disease and the managed care environment. <b>2001</b> , 14, 168-78	8
1436	Cost-effectiveness of colorectal cancer screening. <b>2001</b> , 219, 44-50	29
1435	Cost-effectiveness analysis in radiology. <b>2001</b> , 219, 611-20	57
1434	Resource cost analysis of cervical spine trauma radiography. <b>2001</b> , 220, 581-7	20

1433	The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. <b>2001</b> , 164, 2057-66	43
1432	Decision analysis: a basic overview for the pediatric surgeon. <b>2002</b> , 11, 46-54	3
1431	Abdominal aortic aneurysms: cost-effectiveness of elective endovascular and open surgical repair. <b>2002</b> , 225, 337-44	51
1430	Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. <b>2002</b> , 165, 540-50	141
1429	Assessing Outcomes in Critical Care. <b>2002</b> , 17, 103-111	8
1428	Cumulative risk for developing end-stage renal disease in the US population. <b>2002</b> , 13, 1635-44	108
1427	Long-term impact of Johnson & Johnson's Health & Wellness Program on health care utilization and expenditures. <b>2002</b> , 44, 21-9	84
1426	Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach. <b>2002</b> , 27, S94-9	77
1425	Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. <b>2002</b> , 113, 400-8	102
1424	Dyspepsia management in primary care: a decision analysis of competing strategies. <b>2002</b> , 122, 1270-85	97
1423	COST-EFFECTIVENESS ANALYSIS IN THE REAL WORLD: THE CASE OF STATINS. <b>2002</b> , 19, 381-396	
1422	Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. <b>2002</b> , 20, 1-7	59
1421	Do HEDIS measures reflect cost-effective practices?. <b>2002</b> , 23, 276-89	15
1420	Cost-effectiveness analysis of colorectal cancer treatments. <b>2002</b> , 38, 953-63	22
1419	Paying for prevention standardizing the measurement of the value of health care interventions. <b>2002</b> , 29, 613-43, v	
1418	Cost-Effectiveness of Venous Thromboembolism Prophylaxis after Total Hip Replacement. <b>2002</b> , 17, 126-133	4
1417	Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. <b>2002</b> , 20, 263-73	12
1416	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. <b>2002</b> , 10, 518-27	78

1415	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. <b>2002</b> , 23, 757-73	7
1414	Economic analyses and clinical practice guidelines: why not a match made in heaven?. <b>2002</b> , 17, 235-7	9
1413	Cost-effectiveness of epilepsy therapy: how should treatment effects be measured?. <b>2002</b> , 43 Suppl 4, 17-24	10
1412	Pharmaco-economics of blood transfusion safety: review of the available evidence. <b>2002</b> , 83, 146-55	51
1411	Prophylactic cranial irradiation revisited: cost-effectiveness and quality of life in small-cell lung cancer. <b>2002</b> , 52, 68-74	25
1410	The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. <b>2002</b> , 53, 934-41	7
1409	Economic evaluation in long-term clinical trials. <b>2002</b> , 21, 2879-88	10
1408	Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences. <b>2002</b> , 86, 851-7	37
1407	Evidence-based behavioral medicine: what is it and how do we achieve it?. <b>2003</b> , 26, 161-71	292
1406	Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?. <b>2003</b> , 37, 249-52	4
1405	Time-to-event modeling of competing risks with intervening states in transplantation. <b>2003</b> , 3, 192-202	18
1404	Cost-effectiveness of intracoronary ultrasound for percutaneous coronary interventions. <b>2003</b> , 91, 143-7	23
1403	Decision science and cervical cancer. <b>2003</b> , 98, 2003-8	12
1402	Logical inconsistencies in survey respondents' health state valuations -- a methodological challenge for estimating social tariffs. <b>2003</b> , 12, 529-44	76
1401	The value of the change in health in Sweden 1980/81 to 1996/97. <b>2003</b> , 12, 637-54	27
1400	Liver transplantation is effective, but is it cost-effective?. <b>2003</b> , 9, 1308-11	4
1399	Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data. <b>2003</b> , 1, 12	77
1398	A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases. <b>2003</b> , 6, 90-7	248

1397	The impact of including passive benefits in cost-effectiveness analysis: the case of automated external defibrillators on commercial aircraft. <b>2003</b> , 6, 466-73	9
1396	The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. <b>2003</b> , 6, 584-94	37
1395	Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. <b>2003</b> , 17, 1021-30	25
1394	Evidence-based ethics and the care and outcome of extremely premature infants. <b>2003</b> , 30, 363-87	59
1393	34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective?. <b>2003</b> , 41, 1906-17	39
1392	Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy : cost-effectiveness in refractory epilepsy. <b>2003</b> , 23, 225-32	8
1391	A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. <b>2003</b> , 25, 611-34	26
1390	Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. <b>2003</b> , 48, 553-63	53
1389	Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. <b>2003</b> , 14, S395-404	136
1388	Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metodologia e applicazione di un algoritmo farmaco-economico. <b>2003</b> , 5, 53-67	34
1387	Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. <b>2003</b> , 21, 477-96	48
1386	Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. <b>2003</b> , 21, 1001-24	43
1385	The impact of exacerbations on the asthmatic patient's preference scores. <b>2003</b> , 40, 615-23	27
1384	Switching therapy in health economics trials: confronting the confusion. <b>2003</b> , 23, 335-40	5
1383	MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. <b>2003</b> , 108, 1779-83	48
1382	Validity of standard gamble utilities as measured by transplant readiness in lung transplant candidates. <b>2003</b> , 23, 435-40	10
1381	The use of economic modeling to determine the hospital costs associated with nosocomial infections. <b>2003</b> , 36, 1424-32	94
1380	Cost-effectiveness of different postoperative analgesic treatments. <b>2003</b> , 4, 1507-19	4

1379	Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. <b>2003</b> , 23, 480-8	45
1378	Chapter 15: Public health policy and cost-effectiveness analysis. <b>2003</b> , 102-10	33
1377	Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension. <b>2003</b> , 181, 1653-61	17
1376	Costs and caregiver consequences of early supported discharge for stroke patients. <b>2003</b> , 34, 528-36	89
1375	Regional variation in the cost effectiveness of childhood hepatitis A immunization. <b>2003</b> , 22, 904-14	40
1374	Cost-Utility Analysis of Therapy for Amblyopia. <b>2003</b> , 4, 102-103	
1373	Cost-effective Antiemesis. <b>2003</b> , 41, 145-64	7
1372	Should radon be reduced in homes? A cost-effect analysis. <b>2003</b> , 84, 227-35	19
1371	Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. <b>2003</b> , 31, 1-11	216
1370	Economic evaluation of new therapies in critical illness. <b>2003</b> , 31, S7-16	52
1369	CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. <b>2003</b> , 23, 279-87; ; quiz 443-4	31
1368	Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. <b>2003</b> , 30, 859-65	10
1367	It is money that matters: decision analysis and cost-effectiveness analysis. <b>2003</b> , 106-16	23
1366	Invited Paper D Industry perspective regarding outcomes research in oncology. <b>2004</b> , 623-638	
1365	Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. <b>2004</b> , 233, 729-39	45
1364	Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. <b>2004</b> , 110, 1960-6	80
1363	Value of information literature analysis: a review of applications in health risk management. <b>2004</b> , 24, 287-98	122
1362	Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. <b>2004</b> , 96, 316-25	59

1361	Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids. <b>2004</b> , 230, 207-13	37
1360	Probabilistic Benefit-Cost Analysis for Earthquake Damage Mitigation: Evaluating Measures for Apartment Houses in Turkey. <b>2004</b> , 20, 171-203	88
1359	Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. <b>2004</b> , 22, 4971-8	139
1358	An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. <b>2004</b> , 91, 84-91	50
1357	A cost-utility analysis of neonatal circumcision. <b>2004</b> , 24, 584-601	43
1356	Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. <b>2004</b> , 19, 1159-72	119
1355	Discounting health outcomes in economic evaluation: the ongoing debate. <b>2004</b> , 7, 397-401	119
1354	Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. <b>2004</b> , 7, 518-28	537
1353	Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. <b>2004</b> , 7, 602-9	46
1352	Systematic assessment of decision models in Parkinson's disease. <b>2004</b> , 7, 610-26	20
1351	Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors. <b>2004</b> , 19, 1181-91	27
1350	Use of B-type natriuretic peptide for the management of women with dyspnea. <b>2004</b> , 94, 1510-4	38
1349	Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. <b>2004</b> , 191, 1070-6	41
1348	Integrating ethical enquiry and health technology assessment: limits and opportunities for efficiency and equity. <b>2004</b> , 2, 103-117	8
1347	Post-ICU mortality in critically ill infected patients: an international study. <b>2005</b> , 31, 56-63	17
1346	Just give me a number! Practical values for the social discount rate. <b>2004</b> , 23, 789-812	110
1345	[Health economic studies in dermatology--review of the literature, evaluation and practical aspects]. <b>2004</b> , 2, 279-85	2
1344	Chronic obstructive pulmonary disease: is there a case for early intervention?. <b>2004</b> , 117 Suppl 12A, 3S-10S	5



1343	Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. <b>2004</b> , 43, 386-97	24
1342	Critical appraisal of published economic evaluations of home care for the elderly. <b>2004</b> , 39, 255-67	2
1341	The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. <b>2004</b> , 50, 129-46	59
1340	Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. <b>2004</b> , 22, 445-76	9
1339	The role of cost-effectiveness analysis in the era of pharmacogenomics. <b>2004</b> , 22, 481-93	82
1338	Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. <b>2004</b> , 18, 617-28	40
1337	Evaluation and review of pharmacoeconomic models. <b>2004</b> , 5, 1867-80	24
1336	Métodos de análisis económico de las decisiones diagnósticas y terapéuticas. <b>2004</b> , 95, 1-13	2
1335	Impact of ventilator-associated pneumonia on resource utilization and patient outcome. <b>2004</b> , 25, 1090-6	67
1334	Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. <b>2004</b> , 25, 563-9	17
1333	Análisis coste-efectividad en procesos que requieren ventilación mecánica. Estudio de los GRD 475 y 483. <b>2004</b> , 28, 349-355	2
1332	Pharmacoeconomic analysis of bempiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. <b>2004</b> , 22, 885-94	20
1331	Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. <b>2004</b> , 71, 445-62	25
1330	Thiazolidinediones for Diabetes Mellitus. <b>2004</b> , 12, 363-375	
1329	Pharmacoeconomic implications of new therapies in sepsis. <b>2004</b> , 22, 895-906	46
1328	[Cost-effectiveness analysis: a readers' guide]. <b>2004</b> , 21, S47-55	0
1327	Cost-utility analysis for endoscopic sinus surgery. <b>2004</b> , 130, 31-8	17
1326	Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease. <b>2004</b> , 148, 106-13	31

1325	Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. <b>2004</b> , 116, 816-28	30
1324	A methodological guide to performing a cost-utility study comparing surgical techniques. <b>2004</b> , 12, 179-87	14
1323	Hospital discharge to care facility: a patient-centered outcome for the evaluation of intensive care for octogenarians. <b>2004</b> , 126, 1583-91	50
1322	Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. <b>2004</b> , 32, 137-43	87
1321	Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units. <b>2004</b> , 32, 126-30	60
1320	COMORBIDITIES. <b>2004</b> , 5, 128-129	
1319	The financial implications of coverage of smoking cessation treatment by managed care organizations. <b>2004</b> , 41, 57-69	36
1318	Decision analysis and economic modelling: a primer. <b>2004</b> , 16, 535-42	32
1317	Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. <b>2004</b> , 16, 519-26	27
1316	Clinical and educational telepsychiatry applications: a review. <b>2004</b> , 49, 12-23	161
1315	Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease. <b>2004</b> , 1, 7-16	35
1314	Pertussis immunization of adolescents in the United States: an economic evaluation. <b>2005</b> , 24, S75-82	56
1313	Alcohol interventions for trauma patients treated in emergency departments and hospitals: a cost benefit analysis. <b>2005</b> , 241, 541-50	229
1312	Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. <b>2005</b> , 39, 69-77	31
1311	BARRETT ESOPHAGUS: MORE QUESTIONS THAN ANSWERS. <b>2005</b> , 6, 4-6	
1310	Use of time studies for determining intervention costs. <b>2005</b> , 54, 280-4	14
1309	Rethinking Environmental Performance from a Public Health Perspective: A Comparative Industry Analysis. <b>2005</b> , 9, 143-167	6
1308	Can the Nation Afford ICDs for All Patients With Severe Cardiomyopathy?. <b>2005</b> , 14, 36-41	

1307	Early discharge from obstetrics-pediatrics at the Hospital de Valme, with domiciliary follow-up. <b>2005</b> , 193, 714-26	28
1306	The evaluation of rectal bleeding in adults. A cost-effectiveness analysis comparing four diagnostic strategies. <b>2005</b> , 20, 81-90	15
1305	B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. <b>2005</b> , 67, 278-84	51
1304	Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. <b>2005</b> , 8, 105-16	27
1303	Growth and quality of the cost-utility literature, 1976-2001. <b>2005</b> , 8, 3-9	114
1302	Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. <b>2005</b> , 15, 209-17	7
1301	Determinants of health utility in lung and heart-lung transplant recipients. <b>2005</b> , 5, 103-9	21
1300	Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis. <b>2005</b> , 5, 12	20
1299	Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. <b>2005</b> , 103, 1644-51	44
1298	Capecitabine plus docetaxel combination therapy. <b>2005</b> , 103, 2455-65	20
1297	Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. <b>2005</b> , 52, 2366-75	6
1296	Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia--a decision analysis. <b>2005</b> , 16, 19-28; discussion 28	45
1295	The costs for persons sick-listed more than one month because of low back or neck problems. A two-year prospective study of Swedish patients. <b>2005</b> , 14, 337-45	95
1294	Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. <b>2005</b> , 14, 95-105	75
1293	The clinical and economic implications of pharmacogenomics. <b>2005</b> ,	
1292	Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA. <b>2005</b> , 18, 345-67	37
1291	Is antibiotic prophylaxis for bacterial endocarditis cost-effective?. <b>2005</b> , 25, 308-20	42
1290	Analysis of aspirin-associated risks in healthy individuals. <b>2005</b> , 39, 51-7	5

1289	Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. <b>2005</b> , 112, 3745-53	32
1288	Quality of abstracts of papers reporting original cost-effectiveness analyses. <b>2005</b> , 25, 424-8	25
1287	Cost-effectiveness of whole-body CT screening. <b>2005</b> , 234, 415-22	82
1286	Decision analysis and simulation modeling for evaluating diagnostic tests on the basis of patient outcomes. <b>2005</b> , 185, 581-90	13
1285	Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. <b>2005</b> , 111, 165-72	38
1284	Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. <b>2005</b> , 23, 5171-7	21
1283	Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. <b>2005</b> , 23, 8877-83	31
1282	A synthesis of cost-utility analysis literature in infectious disease. <b>2005</b> , 5, 383-91	15
1281	Costo-efficacia di irbesartan in pazienti con diabete di tipo 2, ipertensione e nefropatia: prospettiva italiana. <b>2005</b> , 7, 43-57	2
1280	Come assegnare un valore al tempo del paziente e del caregiver. <b>2005</b> , 7, 219-230	
1279	Valuing patient and caregiver time: a review of the literature. <b>2005</b> , 23, 449-59	81
1278	Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. <b>2005</b> , 23, 927-44	12
1277	Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. <b>2005</b> , 104, 213-23	11
1276	[Morbidity and cost of rotavirus infections in France]. <b>2005</b> , 35, 492-9	24
1275	Cost-utility analysis of tympanomastoidectomy for adults with chronic suppurative otitis media. <b>2005</b> , 133, 352-6	9
1274	Atrial fibrillation and quality of life: clarity or evidence-based confusion?. <b>2005</b> , 149, 4-6	4
1273	The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data. <b>2005</b> , 140, 679-87	42
1272	Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. <b>2005</b> , 118, 625-35	24

1271	An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer. <b>2005</b> , 190, 406-11	23
1270	Quality-of-Life Utility Values for Erectile Function and Sildenafil Treatment. <b>2005</b> , 25, 99-105	19
1269	Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. <b>2005</b> , 235, 361-70	59
1268	Operating expenses for the diagnosis and treatment of peripheral vascular disease in an academic interventional radiology department: cost calculations according to a microeconomic method. <b>2006</b> , 17, 85-94	13
1267	Quality-of-life valuations of advanced breast cancer by New Zealand women. <b>2006</b> , 24, 281-92	17
1266	Quality-of-life valuations of advanced breast cancer by New Zealand women. <b>2006</b> , 24, 415-6; author reply 416-7	2
1265	Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. <b>2006</b> , 24, 767-81	66
1264	Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. <b>2006</b> , 7, 133-9	22
1263	Cost-effectiveness of treating esophageal varices. <b>2006</b> , 10, 679-89, xi	6
1262	Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. <b>2006</b> , 27, 1304-12	33
1261	Primer: using decision analysis to improve clinical decision making in urology. <b>2006</b> , 3, 439-48	11
1260	Considerations of cost-effectiveness for new radiation oncology technologies. <b>2006</b> , 3, 278-88	4
1259	Impact of discussion on preferences elicited in a group setting. <b>2006</b> , 4, 22	10
1258	A pilot Internet "value of health" panel: recruitment, participation and compliance. <b>2006</b> , 4, 90	9
1257	The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <b>2006</b> , 47, 2310-8	171
1256	Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. <b>2006</b> , 38, 497-505	24
1255	Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. <b>2006</b> , 24, 81-92	22
1254	An evaluation of emergency physician selection of observation unit patients. <b>2006</b> , 24, 271-9	26

1253	Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. <b>2006</b> , 151, 471-7	52
1252	A comparison of individual and social time trade-off values for health states in the general population. <b>2006</b> , 76, 359-70	95
1251	Economic analysis in hand surgery. <b>2006</b> , 31, 664-8	7
1250	Cost utility for penetrating keratoplasty in patients with poor binocular vision. <b>2006</b> , 113, 2176-80	15
1249	Cost-effectiveness of treating multidrug-resistant tuberculosis. <b>2006</b> , 3, e241	74
1248	The long-term health and economic benefits of DOTS implementation in Ecuador. <b>2006</b> , 97, 14-9	2
1247	Cost-effectiveness analysis of sedation and analgesia regimens during fracture manipulation in the pediatric emergency department. <b>2006</b> , 22, 729-36	18
1246	Decision analysis in obstetrics and gynecology. <b>2006</b> , 61, 602-7	5
1245	A cost/utility analysis of open reduction and internal fixation versus cast immobilization for acute nondisplaced mid-waist scaphoid fractures. <b>2006</b> , 117, 1223-35; discussion 1236-8	79
1244	Performance of the EQ-5D in patients with irritable bowel syndrome. <b>2006</b> , 9, 90-7	45
1243	Trends in the measurement of health utilities in published cost-utility analyses. <b>2006</b> , 9, 213-8	102
1242	Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. <b>2006</b> , 9, 281-91	7
1241	Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. <b>2006</b> , 94, 1122-9	101
1240	The association between symptom burdens and utility in Chinese cancer patients. <b>2006</b> , 15, 1427-38	11
1239	A review of health care models for coronary heart disease interventions. <b>2006</b> , 9, 311-24	19
1238	Population-based mammography screening results in substantial savings in treatment costs for fatal breast cancer. <b>2006</b> , 98, 143-50	9
1237	Comments on "Health economic evaluation in lumbar spinal fusion. A systematic literature review anno 2005". <b>2006</b> , 15, 1174-5	3
1236	[Value-based medicine in ophthalmology]. <b>2006</b> , 103, 493-500	6

1235	The total costs of a displaced femoral neck fracture: comparison of internal fixation and total hip replacement. A randomised study of 146 hips. <b>2006</b> , 30, 1-6	38
1234	The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea. <b>2006</b> , 49, 629-36	6
1233	Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. <b>2006</b> , 6, 209	15
1232	Can a disease-specific education program augment self-management skills and improve Health-Related Quality of Life in people with hip or knee osteoarthritis?. <b>2006</b> , 7, 90	20
1231	Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening. <b>2006</b> , 6, 14	21
1230	Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. <b>2006</b> , 12, 736-46	57
1229	Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. <b>2006</b> , 17, 785-93	24
1228	An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. <b>2006</b> , 17, 381-90	36
1227	An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. <b>2006</b> , 29, 1237-41	63
1226	A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease. <b>2006</b> , 13, 515-22	9
1225	Cost Outcomes and Social Work Practice. <b>2006</b> , 16, 5-8	4
1224	The new drugs advent: clinical or economic outcomes?. <b>2006</b> , 17 Suppl 2, ii88-90	1
1223	Cost-effectiveness of drug-eluting stents: real-world scrutiny of the BASKET trial of real-world usage. <b>2006</b> , 3, 305-9	2
1222	Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. <b>2006</b> , 24, 4116-22	57
1221	The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. <b>2006</b> , 29, 259-64	44
1220	Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. <b>2007</b> , 25, 625-33	114
1219	Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. <b>2007</b> , 46, 153-64	43
1218	Intense cardiac troponin surveillance for long-term benefits is cost-effective in patients undergoing open abdominal aortic surgery: a decision analysis model. <b>2007</b> , 105, 1346-56, table of contents	8

1217	An economic analysis of the timing of microsurgical reconstruction in brachial plexus birth palsy. <b>2007</b> , 89, 970-8	16
1216	N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. <b>2007</b> , 115, 3103-10	251
1215	Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. <b>2007</b> , 44, 1040-8	23
1214	Economic evaluations of single- versus double-embryo transfer in IVF. <b>2007</b> , 13, 5-13	49
1213	A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. <b>2007</b> , 27, 789-821	25
1212	Simplified pharmacoeconomics of critical care and severe sepsis. <b>2007</b> , 22, 283-93	3
1211	Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. <b>2007</b> , 26, 186-94	41
1210	Quality-of-life assessment when there is a loss of income. <b>2007</b> , 27, 27-33	14
1209	Interpreting the economic literature in oncology. <b>2007</b> , 25, 196-202	24
1208	Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. <b>2007</b> , 105, 1615-28, table of contents	478
1207	Measuring the cost-effectiveness of technologic change in the treatment of pediatric traumatic brain injury. <b>2007</b> , 63, S113-20; discussion S121	3
1206	Influence of economic evaluations on public health policy. <b>2007</b> , 18, 28-32	2
1205	The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. <b>2007</b> , 19, 733-9	8
1204	An economic evaluation of prolonged mechanical ventilation. <b>2007</b> , 35, 1918-27	141
1203	Updated evaluation of the cost-effectiveness of lung volume reduction surgery. <b>2007</b> , 131, 823-832	41
1202	Implementation of early goal-directed therapy for severe sepsis and septic shock: A decision analysis. <b>2007</b> , 35, 2090-100	58
1201	Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. <b>2007</b> , 131, 1424-34	56
1200	Resource use and costs associated with different states of breast cancer. <b>2007</b> , 23, 223-31	49



1199	Cost-effectiveness of abdominal aortic aneurysm repair: a systematic review. <b>2007</b> , 23, 205-15	24
1198	Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. <b>2007</b> , 154, 899-907	22
1197	The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning. <b>2007</b> , 86, 253-64	41
1196	Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internet. <b>2007</b> , 43, 104-13	7
1195	Does providing cost-effectiveness information change coverage priorities for citizens acting as social decision makers?. <b>2007</b> , 83, 65-72	16
1194	Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. <b>2007</b> , 118, 88-96	21
1193	Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. <b>2007</b> , 22, 177-87	60
1192	Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. <b>2007</b> , 23, 1187-97	40
1191	Choice of modelling technique for evaluating health care interventions. <b>2007</b> , 58, 168-176	45
1190	Tools for Assessment of Cardiovascular Tests and Therapies. <b>2007</b> , 1-34	
1189	Trends in cost effectiveness analyses in orthopaedic surgery. <b>2007</b> , 457, 42-8	50
1188	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <b>2007</b> , 56, 1676-84	82
1187	Efficacy and cost-effectiveness of physiotherapy following glenohumeral joint distension for adhesive capsulitis: a randomized trial. <b>2007</b> , 57, 1027-37	69
1186	Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. <b>2007</b> , 45, 870-8	35
1185	Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. <b>2007</b> , 8, 42	14
1184	A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). <b>2007</b> , 48, 173-80	26
1183	Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. <b>2008</b> , 158, 351-9	60
1182	The value of health care--a matter of discussion in Germany. <b>2007</b> , 7, 1	122

1181	Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. <b>2007</b> , 7, 1515-25	53
1180	A cost-utility analysis of treatments for malignant liver tumours: a pilot project. <b>2007</b> , 9, 42-51	3
1179	Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. <b>2007</b> , 8, 145-51	34
1178	Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. <b>2007</b> , 257, 330-6	20
1177	Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. <b>2007</b> , 26, 531-40	65
1176	Outcome measures in systemic sclerosis: an update on instruments and current research. <b>2007</b> , 9, 151-7	49
1175	The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. <b>2008</b> , 109, 559-66	40
1174	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. <b>2008</b> , 17, 453-62	58
1173	[Economic aspects of prevention]. <b>2008</b> , 49, 146-53	5
1172	Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. <b>2008</b> , 17, 1317-22	41
1171	Pharmacoeconomics is coming of age. <b>2008</b> , 84, 188-90	2
1170	Quality-initiated prophylactic antibiotic use in laparoscopic-assisted vaginal hysterectomy. <b>2008</b> , 48, 592-5	14
1169	Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population. <b>2008</b> , 11, 295-303	93
1168	Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. <b>2008</b> , 11, 853-61	8
1167	Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans. <b>2008</b> , 11, 1170-7	35
1166	The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease. <b>2008</b> , 56, 413-20	85
1165	Development and first assessment of a questionnaire for health care utilization and costs for cardiac patients. <b>2008</b> , 8, 187	11
1164	Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. <b>2008</b> , 58, 231-44	65

1163	Lower recurrence risk through mammographic screening reduces breast cancer treatment costs. <b>2008</b> , 17, 550-4	4
1162	Cost-Effectiveness of B-Type Natriuretic Peptide Testing. <b>2008</b> , 14, 35-37	8
1161	Cost-effectiveness of B-type natriuretic peptide testing. <b>2008</b> , 14, 35-7	4
1160	An economic evaluation of the expanded food and nutrition education program. <b>2008</b> , 40, 134-43	26
1159	Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. <b>2008</b> , 93, 2173-80	139
1158	Coste-efectividad del manejo de la hipercolesterolemia familiar con estrategias de tratamiento preventivo basadas en atorvastatina. <b>2008</b> , 61, 382-393	15
1157	Cost-Effectiveness of Managing Familial Hypercholesterolemia Using Atorvastatin-Based Preventive Therapy. <b>2008</b> , 61, 382-393	1
1156	Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. <b>2008</b> , 6, 113-35	11
1155	Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. <b>2008</b> , 26, 513-36	13
1154	Future costs in cost effectiveness analysis. <b>2008</b> , 27, 809-818	45
1153	The quality of life associated with presbyopia. <b>2008</b> , 145, 618-622	42
1152	A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. <b>2008</b> , 115, 1039-1045.e5	74
1151	Cost and cost-effectiveness of childhood vaccination against rotavirus in France. <b>2008</b> , 26, 706-15	54
1150	Funding of drugs: do vaccines warrant a different approach?. <b>2008</b> , 8, 727-33	84
1149	Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. <b>2008</b> , 26, 17-32	45
1148	An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. <b>2008</b> , 26, 329-39	24
1147	Modelling approaches: the case of schizophrenia. <b>2008</b> , 26, 633-48	36
1146	Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. <b>2008</b> , 12, 235-51	24

1145	An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. <b>2008</b> , 15, 76-83	20
1144	Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. <b>2008</b> , 158, 841-51	85
1143	Incorporaci3n de los costes futuros en los an3lisis farmacoecon3micos: principios y pr3ctica. <b>2008</b> , 5, 35-38	
1142	Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex. <b>2008</b> , 15, 347-53	34
1141	Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. <b>2008</b> , 35, 775-84	47
1140	Twenty years of cost-effectiveness analysis in medical imaging: are we improving?. <b>2008</b> , 249, 917-25	37
1139	Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US. <b>2008</b> , 24, 2905-18	46
1138	Cost-effectiveness of natalizumab in multiple sclerosis. <b>2008</b> , 8, 11-21	5
1137	Erythropoietic agents for anemia of critical illness. <b>2008</b> , 65, 540-6	8
1136	Assessment of health-related quality of life in menopause and aging. <b>2008</b> , 11, 93-107	25
1135	Evaluating the evidence: is there a rigid hierarchy?. <b>2008</b> , 118, 1675-84	139
1134	Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. <b>2008</b> , 248, 169-78	53
1133	Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. <b>2008</b> , 191, 1308-19	15
1132	Cost-effectiveness analysis of periacetabular osteotomy. <b>2008</b> , 90, 1447-56	41
1131	Cost-Effectiveness of Needle and Syringe Exchange for the Prevention of HIV in New York City. <b>2008</b> , 7, 229-240	11
1130	Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. <b>2008</b> , 112, 56-63	15
1129	Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. <b>2008</b> , 215, 33-42	32
1128	Impact of hospital volume on the economic value of computer navigation for total knee replacement. <b>2008</b> , 90, 1492-500	73

1127	[Economic evaluation in health: applications in infectious diseases]. <b>2009</b> , 25, 2543-52	18
1126	Using observational data for decision analysis and economic analysis. <b>2009</b> , 91 Suppl 3, 73-9	19
1125	Generation of a Danish TTO value set for EQ-5D health states. <b>2009</b> , 37, 459-66	171
1124	Health-related quality-of-life assessment in GI cancer randomized trials: improving the impact on clinical practice. <b>2009</b> , 9, 559-67	10
1123	Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. <b>2009</b> , 18, 2677-84	2
1122	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop Competence and Training Statement on Prevention of Cardiovascular Disease). <b>2009</b> , 120, e100-26	21
1121	Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. <b>2009</b> , 2, 362-9	99
1120	The appropriateness of imaging: a comprehensive conceptual framework. <b>2009</b> , 251, 637-49	46
1119	Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. <b>2009</b> , 179, 1055-60	76
1118	Hepatocellular adenoma: cost-effectiveness of different treatment strategies. <b>2009</b> , 252, 737-46	36
1117	CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. <b>2009</b> , 253, 734-44	54
1116	A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]. <b>2009</b> , 29, 7-14	2
1115	When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. <b>2009</b> , 34, 2227-36	70
1114	Cost, effectiveness, and cost-effectiveness. <b>2009</b> , 2, 49-54	27
1113	Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. <b>2009</b> , 27, 5383-9	20
1112	Statin cost-effectiveness in the United States for people at different vascular risk levels. <b>2009</b> , 2, 65-72	45
1111	Decision Analysis and Cost-effectiveness Analysis. <b>2009</b> , 21, 216-222	28
1110	Ageing diseases--do they prevent preventive health care from saving costs?. <b>2009</b> , 18, 355-62	13

1109	Evaluating the cost-effectiveness of cancer patient navigation programs: conceptual and practical issues. <b>2009</b> , 115, 5394-403	37
1108	Technology and the issue of cost/benefit in diabetes. <b>2009</b> , 25 Suppl 1, S34-44	17
1107	Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees. <b>2009</b> , 10, 47-55	47
1106	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. <b>2009</b> , 117, 577-89	49
1105	Cost effectiveness of internet interventions: review and recommendations. <b>2009</b> , 38, 40-5	185
1104	Composite measures for hospital quality using quality-adjusted life years. <b>2009</b> , 28, 1238-54	4
1103	Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. <b>2009</b> , 15, 451-9	27
1102	Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. <b>2009</b> , 17, 2176-81	57
1101	Evaluation of cost effectiveness for conservative and active management strategies for acoustic neuroma. <b>2009</b> , 34, 438-46	19
1100	Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. <b>2009</b> , 33, 1440-9	13
1099	Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. <b>2009</b> , 12, 1-9	10
1098	Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. <b>2009</b> , 12, 217-25	41
1097	Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. <b>2009</b> , 12, 888-98	30
1096	Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. <b>2009</b> , 12, 1106-17	14
1095	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. <b>2009</b> , 12, 1086-99	55
1094	Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: a cost-utility analysis. <b>2009</b> , 91, 580-8	14
1093	Utilization of health technologies-Do not look where there is a light; shine your light where there is a need to look! Relating national health goals with resource allocation decision-making; illustration through examining the Israeli healthcare system. <b>2009</b> , 92, 268-75	3
1092	Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. <b>2009</b> , 27, 4930-7	10

1091	Cost-utility analysis of screening and laser treatment of retinopathy of prematurity. <b>2009</b> , 13, 186-90	24
1090	The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. <b>2009</b> , 136, 193-9	9
1089	The cost-effectiveness of nonsurgical versus surgical treatment for carpal tunnel syndrome. <b>2009</b> , 34, 1193-200	34
1088	Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure. <b>2009</b> , 27, 293-302	34
1087	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing	44
1086	Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. <b>2009</b> , 54, 2358-62	127
1085	Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. <b>2009</b> , 70, 690-699.e6	58
1084	Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. <b>2009</b> , 27, 341-54	22
1083	Simulation of the cost-effectiveness of malaria vaccines. <b>2009</b> , 8, 127	29
1082	The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. <b>2009</b> , 7, 193-205	34
1081	Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. <b>2009</b> , 27, 405-19	17
1080	Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. <b>2009</b> , 27, 873-86	29
1079	Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. <b>2009</b> , 25, 401-11	49
1078	Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. <b>2009</b> , 6, 171-9	74
1077	Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumonia. <b>2009</b> , 30, 759-63	55
1076	Cost-Effectiveness of B-Type Natriuretic Peptide in the Management of Dyspnea. <b>2009</b> , 16, 199-201	
1075	The costs and effectiveness of four HIV counseling and testing strategies in Uganda. <b>2009</b> , 23, 395-401	157
1074	Reducing hospital expenditures with the COPE (Creating Opportunities for Parent Empowerment) program for parents and premature infants: an analysis of direct healthcare neonatal intensive care unit costs and savings. <b>2009</b> , 33, 32-7	58

1073	Cost-effectiveness of routine rapid human immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants in resource-limited settings. <b>2009</b> , 28, 819-25	24
1072	Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization, and cost-effectiveness. <b>2010</b> , 54, 317-23	86
1071	A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. <b>2010</b> , 38, 497-503	94
1070	An economic analysis of hand transplantation in the United States. <b>2010</b> , 125, 589-598	66
1069	Fundamental principles of conducting a surgery economic analysis study. <b>2010</b> , 125, 727-735	31
1068	Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. <b>2010</b> , 54, 258-68	49
1067	Pem and the cost of multicycle maintenance. <b>2010</b> , 5, 1111-2	16
1066	A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes. <b>2010</b> , 13, 655-61	47
1065	Caring for the Uninsured with Prostate Cancer: A Comparison of Four Policy Alternatives in California. <b>2010</b> , 35, 18-26	1
1064	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. <b>2010</b> , 121, 771-6	2
1063	Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?. <b>2010</b> , 26, 605-12	20
1062	Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia. <b>2010</b> , 157, 456-60, 460.e1	17
1061	Cost-effectiveness of external cephalic version for term breech presentation. <b>2010</b> , 10, 3	45
1060	Health economics of blood transfusion safety--focus on sub-Saharan Africa. <b>2010</b> , 38, 53-8	18
1059	Hypofractionated breast radiotherapy: financial and economic consequences. <b>2010</b> , 19, 192-7	65
1058	Cost-utility of treatment of bulimia nervosa. <b>2010</b> , 43, 596-602	19
1057	Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. <b>2010</b> , 85, 255-60	8
1056	Grading Economic Evidence. <b>2010</b> , 114-133	5



1055	The IGNITE (investigation to guide new insight into translational effectiveness) trial: Protocol for a translational study of an evidenced-based wellness program in fire departments. <b>2010</b> , 5, 73	3
1054	A cost utility analysis of interdisciplinary early intervention versus treatment as usual for high-risk acute low back pain patients. <b>2010</b> , 10, 382-95	36
1053	The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. <b>2010</b> , 50, 2461-73	54
1052	Understanding cost-effectiveness. <b>2010</b> , 16, 1707-12	22
1051	Cost-effectiveness analysis in infectious diseases. <b>2010</b> , 16, 1705-6	1
1050	Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. <b>2010</b> , 13, 160-8	17
1049	An ounce of prevention is worth a pound of cure: a cost-effectiveness analysis of incidentally detected aneurysms in functional MRI research. <b>2010</b> , 13, 761-9	7
1048	Health Economics of Antibiotics. <b>2010</b> , 3, 1348-1359	4
1047	Patient time requirements for anticoagulation therapy with warfarin. <b>2010</b> , 30, 206-16	25
1046	A Health-economic Assessment of Cervical Disc Arthroplasty Compared With Allograft Fusion. <b>2010</b> , 25, 133-137	10
1045	Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. <b>2010</b> , 121, 1329-37	28
1044	How much should we invest in preventing childhood obesity?. <b>2010</b> , 29, 372-8	41
1043	A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programs. <b>2010</b> , 105, 1861-9	24
1042	Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. <b>2010</b> , 81, 256-62	25
1041	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. <b>2010</b> , 26, 2315-28	5
1040	The value of trauma center care. <b>2010</b> , 69, 1-10	125
1039	Suspected carotid artery stenosis: cost-effectiveness of CT angiography in work-up of patients with recent TIA or minor ischemic stroke. <b>2010</b> , 256, 585-97	28
1038	Minor head injury: CT-based strategies for management--a cost-effectiveness analysis. <b>2010</b> , 254, 532-40	70

1037	Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis. <b>2010</b> , 256, 836-46	74
1036	The cost-effectiveness of a nonpharmacologic intervention for individuals with dementia and family caregivers: the tailored activity program. <b>2010</b> , 18, 510-9	78
1035	Cost-effectiveness of Down syndrome screening paradigms. <b>2010</b> , 30, 629-42	11
1034	Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. <b>2010</b> , 28, 629-47	20
1033	A cost-utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritis. <b>2010</b> , 35, 379-391.e2	64
1032	Clinical and economic burden of pneumococcal disease in older US adults. <b>2010</b> , 28, 4955-60	97
1031	Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. <b>2010</b> , 13, 33-41	19
1030	Expanding the criteria for BRCA mutation testing in breast cancer survivors. <b>2010</b> , 28, 4214-20	109
1029	Preventing future cancers by testing women with ovarian cancer for BRCA mutations. <b>2010</b> , 28, 675-82	68
1028	Cost-effectiveness of electrocardiography vs. electrocardiography plus limited echocardiography to diagnose LVH in young, newly identified, hypertensives. <b>2010</b> , 23, 592-8	11
1027	Economic Issues and Genomic Medicine. <b>2010</b> , 233-244	
1026	Economic effects of pharmacists on health outcomes in the United States: A systematic review. <b>2010</b> , 67, 1624-34	102
1025	Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index. <b>2010</b> , 28, 201-16	10
1024	Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. <b>2010</b> , 28, 521-38	28
1023	A review and critique of studies reporting utility values for schizophrenia-related health states. <b>2010</b> , 28, 1109-21	14
1022	Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. <b>2010</b> , 14, 375-84	36
1021	Valori di soglia: una scomoda necessit�. <b>2011</b> , 13, 1-4	
1020	Cost-effectiveness of colorectal cancer screening. <b>2011</b> , 33, 88-100	188

1019	Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. <b>2011</b> , 185, 1591-7	45
1018	Rationing and health care reform: not a question of if, but when. <b>2011</b> , 8, 830-7	4
1017	Demythologizing the high costs of pharmaceutical research. <b>2011</b> , 6, 34-50	120
1016	Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. <b>2011</b> , 14, 900-6	36
1015	A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. <b>2011</b> , 14, 836-45	60
1014	Estimating the SF-6D value set for a population-based sample of Brazilians. <b>2011</b> , 14, S108-14	46
1013	EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. <b>2011</b> , 14, 1117-29	51
1012	Cost-effectiveness of raltegravir in HIV/AIDS. <b>2011</b> , 11, 627-39	5
1011	Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis. <b>2011</b> , 9, 259-73	4
1010	Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness. <b>2011</b> , 40, 279-94, vii	20
1009	An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. <b>2011</b> , 36, 1912-8.e1-3	73
1008	A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). <b>2011</b> , 104, 383-9	76
1007	Public health and prevention in Europe: is it cost-effective?. <b>2011</b> , 2, 151-155	0
1006	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. <b>2011</b> , 12, 501-15	29
1005	Assessing physical function and activity for survivors of a critical illness: a review of instruments. <b>2011</b> , 24, 155-66	55
1004	Preoperative blood tests: an expensive tick box exercise. <b>2011</b> , 21, 421-4	1
1003	Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. <b>2011</b> , 6, e22276	14
1002	The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury. <b>2011</b> , 6, e22512	31

1001	The tale of two serologic tests to screen for syphilis--treponemal and nontreponemal: does the order matter?. <b>2011</b> , 38, 448-56	20
1000	Economic analysis of the military health professions scholarship program for neurosurgeons. <b>2011</b> , 69, 525-31; discussion 531-2	5
999	Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. <b>2011</b> , 25, 211-20	37
998	Viewpoint: Economic evaluation of package of care interventions employing clinical guidelines. <b>2011</b> , 16, 97-104	9
997	The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy. <b>2011</b> , 46, 1534-61	37
996	Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?. <b>2011</b> , 13, 783-91	22
995	Patients' self-interested preferences: empirical evidence from a priority setting experiment. <b>2011</b> , 72, 1317-24	5
994	Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. <b>2011</b> , 150, 1286-94	61
993	Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. <b>2011</b> , 158, 257-64.e1-7	32
992	[Economic evaluation of public health interventions]. <b>2011</b> , 25 Suppl 1, 25-31	4
991	Early prevention of pressure ulcers among elderly patients admitted through emergency departments: a cost-effectiveness analysis. <b>2011</b> , 58, 468-78.e3	24
990	Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore. <b>2011</b> , 11, 178	10
989	Health state preferences associated with weight status in children and adolescents. <b>2011</b> , 11, 12	16
988	Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study. <b>2011</b> , 11, 55	20
987	Computerized clinical decision support systems for primary preventive care: a decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes. <b>2011</b> , 6, 87	98
986	Projected numbers of people with movement disorders in the years 2030 and 2050. <b>2011</b> , 26, 2286-90	92
985	Economics of children's environmental health. <b>2011</b> , 78, 98-106	5
984	References. <b>2011</b> , 481-517	

983	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. <b>2011</b> , 63, 65-78	62
982	Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. <b>2011</b> , 184, 1289-98	38
981	Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. <b>2011</b> , 261, 487-98	28
980	Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. <b>2011</b> , 13, 154-62	10
979	Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. <b>2011</b> , 123, 2562-70	259
978	Economic evaluation of caffeine for apnea of prematurity. <b>2011</b> , 127, e146-55	31
977	Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. <b>2011</b> , 29, 2993-3000	63
976	Testing women with endometrial cancer to detect Lynch syndrome. <b>2011</b> , 29, 2247-52	88
975	The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. <b>2011</b> , 34, 622-7	64
974	Cost-Effectiveness Analysis of Unicompartamental Knee Arthroplasty and High Tibial Osteotomy for Treatment of Medial Compartmental Osteoarthritis. <b>2011</b> , 1, 27-37	3
973	A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. <b>2011</b> , 30, 340-8	26
972	Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. <b>2011</b> , 4, 76-84	18
971	Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers. <b>2011</b> , 15, 286-95	10
970	A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. <b>2011</b> , 56, 443-52	10
969	Serologic testing for syphilis in the United States: a cost-effectiveness analysis of two screening algorithms. <b>2011</b> , 38, 1-7	62
968	Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. <b>2011</b> , 20, 522-9	37
967	The \$17.1 billion problem: the annual cost of measurable medical errors. <b>2011</b> , 30, 596-603	182
966	US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. <b>2011</b> , 7, e38s-45s	29

965	Economic Evaluation With Clinical Trials in Neonatology. <b>2011</b> , 12, e69-e75	6
964	Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. <b>2012</b> , 9, e1001347	149
963	Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. <b>2012</b> , 5, 10-6	119
962	Assessing the cost of early intervention in psychosis: a systematic review. <b>2012</b> , 46, 719-34	36
961	Methods in comparative effectiveness research. <b>2012</b> , 30, 4208-14	72
960	Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). <b>2012</b> , 125, 1102-9	215
959	Autism spectrum disorders: a review of measures for clinical, health services and cost-effectiveness applications. <b>2012</b> , 12, 485-503	48
958	Utility outcome assessment of the aging neck following massive weight loss. <b>2012</b> , 147, 26-32	17
957	Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. <b>2012</b> , 125, 2621-9	44
956	Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?. <b>2012</b> , 17, 157-9	4
955	Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery. <b>2012</b> , 94, e35	15
954	The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis. <b>2012</b> , 14, 631-40	30
953	Endogenous patient responses and the consistency principle in cost-effectiveness analysis. <b>2012</b> , 32, 488-97	1
952	Counting the cost: Commentary on a systematic review of cost of early intervention in psychosis. <b>2012</b> , 46, 787-9	3
951	Interpretation of health and vision utilities in low vision patients. <b>2012</b> , 89, 288-95	3
950	The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions. <b>2012</b> , 14, 600-617	32
949	Effectiveness of osteoporosis therapy among frail, older adults: should we carry out more trials?. <b>2012</b> , 8, 461-470	1
948	The cost effectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery. <b>2012</b> , 37, 769-74	76

947	Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. <b>2012</b> , 141, 321-329	35
946	Pressure Ulcer Prevention Program Study: a randomized, controlled prospective comparative value evaluation of 2 pressure ulcer prevention strategies in nursing and rehabilitation centers. <b>2012</b> , 25, 450-64	33
945	Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada. <b>2012</b> , 39, 260-7	30
944	Perspectives on cost-effective medicine and the use of cost-effectiveness analyses. <b>2012</b> , 54, 2-3	3
943	Is surgical fixation for stress-positive unstable ankle fractures cost effective? Results of a multicenter randomized control trial. <b>2012</b> , 26, 652-8	23
942	Economic Analyses alongside Cancer Clinical Trials. <b>2012</b> , 369-386	
941	Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. <b>2012</b> , 13, 939-58	13
940	Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?. <b>2012</b> , 23, 2681-92	11
939	Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. <b>2012</b> , 136, 547-57	13
938	The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). <b>2012</b> , 33, 1117-23	37
937	Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation. <b>2012</b> , 30, 7601-7	15
936	Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. <b>2012</b> , 56, 1015-24.e1	71
935	The economics of antimicrobial stewardship: the current state of the art and applying the business case model. <b>2012</b> , 33, 389-97	21
934	Acellular dermal matrices: economic considerations in reconstructive and aesthetic breast surgery. <b>2012</b> , 39, 187-216	19
933	Screening based on risk for colorectal cancer is the most cost-effective approach. <b>2012</b> , 10, 266-71.e1-6	16
932	Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable. <b>2012</b> , 18, 1533-9	23
931	Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. <b>2012</b> , 28, 11-24, v	44
930	Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. <b>2012</b> , 53, 2371-7	21

929	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. <b>2012</b> , 36, 147-54	27
928	Economic evaluation of strategies to reduce sudden cardiac death in young athletes. <b>2012</b> , 130, e380-9	39
927	QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. <b>2012</b> , 12, 360	11
926	The association of moderate renal dysfunction with impaired preference-based health-related quality of life: third Korean national health and nutritional examination survey. <b>2012</b> , 13, 19	17
925	Promoting advance planning for health care and research among older adults: a randomized controlled trial. <b>2012</b> , 13, 1	33
924	Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. <b>2012</b> , 10, 99	46
923	The value of critical care. <b>2012</b> , 92, 1445-62	13
922	The use of cost-effectiveness analysis for pediatric immunization in developing countries. <b>2012</b> , 90, 762-90	4
921	Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. <b>2012</b> , 72, 789-802	54
920	Measuring Disease Activity and Outcomes in Clinical trials. <b>2012</b> , 661-671	1
919	The cost effectiveness of radiofrequency ablation for Barrett's esophagus. <b>2012</b> , 143, 567-575	124
918	Application of classic utilities to published pediatric cost-utility studies. <b>2012</b> , 12, 219-28	8
917	Monte Carlo simulation of the cost-effectiveness of sample size maintenance programs revealed the need to consider substitution sampling. <b>2012</b> , 65, 1200-11	3
916	Smoke alarm giveaway and installation programs: an economic evaluation. <b>2012</b> , 43, 385-91	9
915	The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. <b>2012</b> , 26, 649-58	196
914	Cost-utility analysis in spine care: a systematic review. <b>2012</b> , 12, 676-90	74
913	A cost-effectiveness analysis of adrenalectomy for nonfunctional adrenal incidentalomas: is there a size threshold for resection?. <b>2012</b> , 152, 1125-32	13
912	Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. <b>2012</b> , 15, 255-60	11



911	Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. <b>2012</b> , 15, 876-86	5
910	Defining patient-reported outcomes in chronic obstructive pulmonary disease: the patient-centered experience. <b>2012</b> , 96, 767-87	6
909	Preoperative localization strategies for primary hyperparathyroidism: an economic analysis. <b>2012</b> , 19, 4202-9	74
908	Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. <b>2012</b> , 7, e32879	8
907	Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. <b>2012</b> , 7, e39640	49
906	The determinants of HIV treatment costs in resource limited settings. <b>2012</b> , 7, e48726	47
905	Use of Teledermatology in the Management of Psoriasis. <b>2012</b> , 18a, 174-178	
904	Measuring the health of populations: explaining composite indicators. <b>2012</b> , 1, 222-8	25
903	[Costs of diseases with long-term survival]. <b>2012</b> , 55, 468-73	1
902	Early hospital discharge of infants born to group B streptococci-positive mothers: a decision analysis. <b>2012</b> , 119, 439-48	7
901	Costs of dengue prevention and incremental cost of dengue outbreak control in Guantanamo, Cuba. <b>2012</b> , 17, 123-32	24
900	Implementing evidence-based changes in emergency department treatment: alternative vitamin therapy for alcohol-related illnesses. <b>2012</b> , 59, 408-12	5
899	Hospital cost analysis of a prospective, randomized trial of early vs interval appendectomy for perforated appendicitis in children. <b>2012</b> , 214, 427-34; discussion 434-5	34
898	What is the value for money of medicines? A registry study. <b>2012</b> , 37, 182-6	4
897	B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. <b>2012</b> , 272, 504-13	22
896	Econometric studies on pharmacist care services are lacking--a call for papers. <b>2012</b> , 20, 69-70	
895	Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. <b>2012</b> , 21, 238-51	94
894	Cost-effectiveness analyses of training: a manager's guide. <b>2013</b> , 11, 20	2

893	Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis. <b>2013</b> , 22, 1055-63	9
892	Cost-Effectiveness Analysis and Cost-Benefit Analysis. <b>2013</b> , 288-306	
891	Empirical evidence of the continuing improvement in cost efficiency of an endoscopic surveillance programme for gastric cancer in Singapore from 2004 to 2010. <b>2013</b> , 13, 139	3
890	Does health information exchange reduce unnecessary neuroimaging and improve quality of headache care in the emergency department?. <b>2013</b> , 28, 176-83	68
889	Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. <b>2013</b> , 14, 26-31	33
888	Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. <b>2013</b> , 19, e228-38	40
887	Cost-effectiveness analysis for imaging techniques with a focus on cardiovascular magnetic resonance. <b>2013</b> , 15, 52	17
886	Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer". <b>2013</b> , 154, 1307-13; discussion 1313-4	31
885	PHARMACOECONOMICS, OUTCOME, AND HEALTH TECHNOLOGY ASSESSMENT RESEARCH IN DRUG DEVELOPMENT. <b>2013</b> , 535-546	
884	Quality of reporting in economic evaluations of interventions to prevent dental caries needs improvement. <b>2013</b> , 13, 109-10	3
883	Comparison of cost-effectiveness of vitamin D screening with that of universal supplementation in preventing falls in community-dwelling older adults. <b>2013</b> , 61, 707-14	19
882	Quality-of-life, health service use, and costs associated with syncope. <b>2013</b> , 55, 370-5	48
881	The moral psychology of rationing among physicians: the role of harm and fairness intuitions in physician objections to cost-effectiveness and cost-containment. <b>2013</b> , 8, 13	7
880	Economic analysis of complementary, alternative, and integrative medicine: considerations raised by an expert panel. <b>2013</b> , 13, 191	12
879	A practical approach for calculating reliable cost estimates from observational data: application to cost analyses in maternal and child health. <b>2013</b> , 11, 343-57	28
878	The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review. <b>2013</b> , 31, 1131-54	16
877	Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent $\beta$ -thalassemia patients. <b>2013</b> , 53, 1722-9	15
876	Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise. <b>2013</b> , 31, 257-67	33

875	An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. <b>2013</b> , 29, 1191-200	3
874	Indirect costs associated with metastatic breast cancer. <b>2013</b> , 16, 1169-78	29
873	Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. <b>2013</b> , 108, 120-32	86
872	Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(?)D) trial. <b>2013</b> , 23, 1739-46	8
871	Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. <b>2013</b> , 61, 1250-8	41
870	Health economic controversy and cost-effectiveness of proton therapy. <b>2013</b> , 23, 134-41	50
869	Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. <b>2013</b> , 19, 1301-9	21
868	Reducing older driver motor vehicle collisions via earlier cataract surgery. <b>2013</b> , 61, 203-11	16
867	How to value technological innovation: a proposal for determining relative clinical value. <b>2013</b> , 144, 5-8	5
866	Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. <b>2013</b> , 26, 527-34	8
865	The economics of pancreas surgery. <b>2013</b> , 93, 711-28	20
864	Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. <b>2013</b> , 18, 325-37	76
863	Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. <b>2013</b> , 22, 1567-76	55
862	Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. <b>2013</b> , 6, 724-31	61
861	Cost-effectiveness in the management of Dupuytren's contracture. A Canadian cost-utility analysis of current and future management strategies. <b>2013</b> , 95-B, 1094-100	47
860	Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. <b>2013</b> , 44, 1676-81	198
859	Cost-effectiveness analysis: comparing single-level cervical disc replacement and single-level anterior cervical discectomy and fusion: clinical article. <b>2013</b> , 19, 546-54	66
858	Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. <b>2013</b> , 57, 1021-6	11

857	Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. <b>2013</b> , 62, 351-364.e19	99
856	Is liver transplantation using organs donated after cardiac death cost-effective or does it decrease waitlist death by increasing recipient death?. <b>2013</b> , 15, 182-9	8
855	The cost-effectiveness of expanded HIV screening in the United States. <b>2013</b> , 27, 795-801	44
854	Utility values in the visually impaired: comparing time-trade off and VisQoL. <b>2013</b> , 90, 843-54	3
853	The societal and economic value of rotator cuff repair. <b>2013</b> , 95, 1993-2000	237
852	Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical care trials. <b>2013</b> , 187, 256-61	33
851	Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. <b>2013</b> , 56, 430-46	41
850	Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. <b>2013</b> , 127, 820-31	82
849	Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. <b>2013</b> , 33, 215-24	8
848	Societal and economic impact of anterior cruciate ligament tears. <b>2013</b> , 95, 1751-9	259
847	What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses. <b>2013</b> , 8, 457-66	9
846	Cost-effectiveness analyses and their role in improving healthcare strategies. <b>2013</b> , 25, 487-93	10
845	Health-related quality of life in children with autoimmune liver disease. <b>2013</b> , 57, 444-50	31
844	Cost-effectiveness of cervical cancer prevention. <b>2013</b> , 56, 55-64	7
843	The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. <b>2013</b> , 56, 587-97	25
842	Key questions to be answered. <b>2013</b> , 19, 224-5	2
841	Cost effectiveness analysis for nursing research. <b>2013</b> , 62, 279-85	12
840	Cost-effectiveness of the community-based management of severe acute malnutrition by community health workers in southern Bangladesh. <b>2013</b> , 28, 386-99	67

839	Cost-effectiveness analysis of infant feeding strategies to prevent mother-to-child transmission of HIV in South Africa. <b>2013</b> , 12, 151-60	6
838	Can donors with high donor risk indices be used cost-effectively in liver transplantation in US Transplant Centers?. <b>2013</b> , 26, 1063-9	4
837	More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation. <b>2013</b> , 27, 289-96	23
836	Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value. <b>2013</b> , 2, 261-71	2
835	Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. <b>2013</b> , 121, 14-24	111
834	Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. <b>2013</b> , 23, 1318-25	9
833	Responsiveness of the EQ-5D to the effects of low vision rehabilitation. <b>2013</b> , 90, 799-805	13
832	An Analysis of the Plastic Surgery Cost-Utility Literature Using a Novel Scoring Tool. <b>2013</b> , 132, 168	2
831	Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. <b>2013</b> , 27, 2883-92	27
830	Brief report: a cost analysis of neuraxial anesthesia to facilitate external cephalic version for breech fetal presentation. <b>2013</b> , 117, 155-9	15
829	Thigh laxity after massive weight loss: a utilities outcomes assessment. <b>2013</b> , 71, 304-7	9
828	Economic Issues and Genomic Medicine. <b>2013</b> , 440-446	
827	Economic evaluation in the field of mental health: conceptual basis. <b>2013</b> , 35, 186-92	5
826	The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis. <b>2013</b> , 8, e61504	27
825	Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. <b>2013</b> , 8, e67910	19
824	Global epidemiology of mental disorders: what are we missing?. <b>2013</b> , 8, e65514	112
823	Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis. <b>2014</b> , 9, e83526	7
822	Quantification of health by scaling similarity judgments. <b>2014</b> , 9, e89091	5

821	The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. <b>2014</b> , 9, e97317	90
820	Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. <b>2014</b> , 9, e107255	31
819	Modeling the cost effectiveness of malaria control interventions in the highlands of western Kenya. <b>2014</b> , 9, e107700	31
818	Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making. <b>2014</b> , 9, e108742	42
817	Cost-effectiveness analysis in minimally invasive spine surgery. <b>2014</b> , 36, E4	41
816	Descriptive analysis of the cost-effectiveness of depressed patients undergoing total knee arthroplasty: an economic decision analysis. <b>2014</b> , 19, 820-6	8
815	Impact of pharmacy worker training and deployment on access to essential medicines and health outcomes in Malawi: protocol for a cluster quasi-experimental evaluation. <b>2014</b> , 9, 156	11
814	Considering productivity loss in cost-effectiveness analysis: a new approach. <b>2014</b> , 15, 787-90	3
813	Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. <b>2014</b> , 3, e000912	22
812	Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach. <b>2014</b> , 12, 471-6	3
811	How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. <b>2014</b> , 12, 216	57
810	Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. <b>2014</b> , 7, 341-50	23
809	Multisite artery disease: a common and challenging clinical condition calling for specific management. <b>2014</b> , 10, 395-407	1
808	Commentary: demonstrating cost-effectiveness in pediatric psychology. <b>2014</b> , 39, 602-11	7
807	Benefit of slow titration of paroxetine to treat depression in the elderly. <b>2014</b> , 29, 544-51	4
806	Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial. <b>2014</b> , 3, e001233	21
805	Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. <b>2014</b> , 19, 892-9	17
804	Estimating EQ-5D values from the Neck Disability Index and numeric rating scales for neck and arm pain. <b>2014</b> , 21, 394-9	11

803	The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. <b>2014</b> , 11 Suppl 2, S105-11	22
802	Variations in cost calculations in spine surgery cost-effectiveness research. <b>2014</b> , 36, E1	55
801	Evaluation of targeted mass cholera vaccination strategies in Bangladesh: a demonstration of a new cost-effectiveness calculator. <b>2014</b> , 91, 1181-1189	19
800	Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. <b>2014</b> , 32, 1015-28	7
799	Economic benefit to society at large of total knee arthroplasty in younger patients: a Markov analysis. <b>2014</b> , 96, 119-26	54
798	Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. <b>2014</b> , 54, 2034-44	22
797	Aid and the Control of Tuberculosis in Papua New Guinea: Is Australia's Assistance Cost-Effective?. <b>2014</b> , 1, 364-378	1
796	Cost-effectiveness of CT angiography and perfusion imaging for delayed cerebral ischemia and vasospasm in aneurysmal subarachnoid hemorrhage. <b>2014</b> , 35, 1714-20	27
795	MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis. <b>2014</b> , 203, 361-71	30
794	Calculating averted caries attributable to school-based sealant programs with a minimal data set. <b>2014</b> , 74, 202-9	9
793	Predicting health utilities for children with autism spectrum disorders. <b>2014</b> , 7, 649-63	24
792	The global burden of mental and substance use disorders: changes in estimating burden between GBD1990 and GBD2010. <b>2014</b> , 23, 239-49	15
791	Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. <b>2014</b> , 20, 2046-55	6
790	A systematic review of economic evaluations of enhanced recovery pathways for colorectal surgery. <b>2014</b> , 259, 670-6	86
789	Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. <b>2014</b> , 28 Suppl 3, S287-99	6
788	Understanding Value in Spine Surgery. <b>2014</b> , 15, 1-5	
787	Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. <b>2014</b> , 24, 6-14	20
786	Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cte d'Ivoire. <b>2014</b> , 66, 294-302	6

785	Should patients with ocular genetic disorders have genetic testing?. <b>2014</b> , 25, 359-65	5
784	Economic evaluation of decompressive craniectomy versus barbiturate coma for refractory intracranial hypertension following traumatic brain injury. <b>2014</b> , 42, 2235-43	14
783	The 5-year cost-effectiveness of anterior cervical discectomy and fusion and cervical disc replacement: a Markov analysis. <b>2014</b> , 39, 1924-33	40
782	Cervical degenerative disease: systematic review of economic analyses. <b>2014</b> , 39, S53-64	23
781	Economic analysis of revision amputation and replantation treatment of finger amputation injuries. <b>2014</b> , 133, 827-840	47
780	The impact of living with severe lower extremity lymphedema: a utility outcomes score assessment. <b>2014</b> , 73, 210-4	14
779	Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. <b>2014</b> , 7, 25-32	20
778	Comparing decisions for malaria testing and presumptive treatment: a net health benefit analysis. <b>2014</b> , 34, 996-1005	6
777	Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa. <b>2014</b> , 12, 20	2
776	Comparative cost-effectiveness analyses of cardiovascular magnetic resonance and coronary angiography combined with fractional flow reserve for the diagnosis of coronary artery disease. <b>2014</b> , 16, 13	21
775	Consensus guidelines for the management of postoperative nausea and vomiting. <b>2014</b> , 118, 85-113	930
774	Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. <b>2014</b> , 7, 78-85	26
773	Tutorial on health economics and outcomes research in nutrition. <b>2014</b> , 38, 5S-16S	4
772	Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood. <b>2014</b> , 23, 779-85	12
771	Calculation of operating expenses for conventional transarterial chemoembolization in an academic medical center: a step toward defining the value of transarterial chemoembolization. <b>2014</b> , 25, 567-74	16
770	Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. <b>2014</b> , 88, 106-14	14
769	If nudge cannot be applied: a litmus test of the readers' stance on paternalism. <b>2014</b> , 76, 297-315	3
768	Systematic assessment of decision-analytic models for chronic myeloid leukemia. <b>2014</b> , 12, 103-15	8



767	Cost-effectiveness of femtosecond laser-assisted cataract surgery versus phacoemulsification cataract surgery. <b>2014</b> , 121, 10-16	72
766	Cost-effectiveness of competing strategies for management of recurrent <i>Clostridium difficile</i> infection: a decision analysis. <b>2014</b> , 58, 1507-14	107
765	Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. <b>2014</b> , 29, 438-46	37
764	Isn't it ironic? Cost-effectiveness and willingness to pay for tolvaptan in the prevention of kidney failure in autosomal dominant polycystic kidney disease. <b>2014</b> , 63, 552-4	2
763	Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea. <b>2014</b> , 7, 141-50	2
762	A cost-utility analysis for prophylactic central neck dissection in clinically nodal-negative papillary thyroid carcinoma. <b>2014</b> , 21, 767-77	13
761	A comparison of injured patient and general population valuations of EQ-5D health states for New Zealand. <b>2014</b> , 12, 21	11
760	Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty. <b>2014</b> , 15, 22	20
759	Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?. <b>2014</b> , 22, 415-30	15
758	Cost effectiveness of mesh prophylaxis to prevent parastomal hernia in patients undergoing permanent colostomy for rectal cancer. <b>2014</b> , 218, 82-91	41
757	A cost-minimization analysis comparing total thyroidectomy alone and total thyroidectomy with prophylactic central neck dissection in clinically nodal-negative papillary thyroid carcinoma. <b>2014</b> , 21, 416-25	7
756	Making the case for cost-effectiveness research. <b>2014</b> , 109, 509-15	9
755	Cost-effectiveness of blood donor screening for <i>Babesia microti</i> in endemic regions of the United States. <b>2014</b> , 54, 889-99	31
754	Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States. <b>2014</b> , 51, 17-24	8
753	Cost, quality, and value in coronary artery bypass grafting. <b>2014</b> , 148, 2729-35.e1	16
752	Trends, productivity losses, and associated medical conditions among toxoplasmosis deaths in the United States, 2000-2010. <b>2014</b> , 91, 959-64	13
751	Simultaneous Bilateral Versus Staged Unilateral Carpal Tunnel Release: A Cost-Effectiveness Analysis. <b>2014</b> , 39, e28-e29	
750	Economic evaluation of diagnostic methods used in dentistry. A systematic review. <b>2014</b> , 42, 1361-71	10

749	Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis. <b>2014</b> , 90, 344-53	9
748	Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. <b>2014</b> , 24, 443-60	21
747	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. <b>2014</b> , 67, 1093-102	9
746	Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. <b>2014</b> , 130, 1146-57	64
745	Evaluation of economic costs of a measles outbreak and outbreak response activities in Keffa Zone, Ethiopia. <b>2014</b> , 32, 4505-4514	18
744	Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong. <b>2014</b> , 46, 27-33	5
743	Cost-effectiveness of a package of interventions for expedited antiretroviral therapy initiation during pregnancy in Cape Town, South Africa. <b>2014</b> , 18, 697-705	15
742	Evaluating the cost-effectiveness of laryngeal examination after elective total thyroidectomy. <b>2014</b> , 21, 3548-56	20
741	Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. <b>2014</b> , 1, 55-62	11
740	Cost-Effectiveness Analysis of Early Reconstruction Versus Rehabilitation and Delayed Reconstruction for Anterior Cruciate Ligament Tears. <b>2014</b> , 42, 1583-91	55
739	Research priorities for economic analyses of prevention: current issues and future directions. <b>2014</b> , 15, 789-98	25
738	Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. <b>2014</b> , 37, 507-23	29
737	The cost savings of expanding Medicaid eligibility to include currently uninsured homeless adults with substance use disorders. <b>2014</b> , 41, 110-24	5
736	Economic evaluations of guideline-based or strategic interventions for the prevention or treatment of chronic wounds. <b>2014</b> , 12, 373-89	20
735	The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. <b>2014</b> , 14, 224	38
734	Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. <b>2014</b> , 14, 296	17
733	The By-Band study: gastric bypass or adjustable gastric band surgery to treat morbid obesity: study protocol for a multi-centre randomised controlled trial with an internal pilot phase. <b>2014</b> , 15, 53	31
732	Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply. <b>2014</b> , 54, 2245-57	23

731	Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. <b>2014</b> , 37, 202-9	76
730	Time to Surgery in the Treatment of Lateral Epicondylitis: A Cost-Effectiveness Analysis. <b>2014</b> , 39, e48-e49	1
729	Costs and cost-effectiveness of periviable care. <b>2014</b> , 38, 56-62	13
728	Cost-effectiveness of revascularization for limb preservation in patients with marginal functional status. <b>2014</b> , 28, 10-7	8
727	Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. <b>2014</b> , 79, 455-65	59
726	Quality, economics, and national guidelines for transcatheter aortic valve replacement. <b>2014</b> , 56, 610-8	12
725	Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. <b>2014</b> , 121, 1855-62	36
724	Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. <b>2014</b> , 134, 908-915.e3	36
723	Cost-utility analysis of repair of reducible ventral hernia. <b>2014</b> , 155, 1081-9	12
722	Cost-effectiveness of revascularization for limb preservation in patients with end-stage renal disease. <b>2014</b> , 60, 369-374.e1	11
721	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. <b>2014</b> , 15, 502	7
720	Constrained resources. 237-299	1
719	Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. <b>2014</b> , 11, 711-7	64
718	Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. <b>2014</b> , 19, 425-36	37
717	A methodological analysis of the plastic surgery cost-utility literature using established guidelines. <b>2014</b> , 133, 584e-592e	3
716	Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. <b>2014</b> , 145, 1347-1356	37
715	Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. <b>2015</b> , 67, 203-15	189
714	Value and Cost Effectiveness of Common Spinal Surgical Procedures. <b>2015</b> , 16, 1-7	

713	Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. <b>2014</b> , 22, 311-9	1
712	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <b>2015</b> , 125, 1866-9	27
711	The Quality of Cost-Utility Analyses in Orthopedic Trauma. <b>2015</b> , 38, e673-80	21
710	Implementing Computerized Provider Order Entry in Acute Care Hospitals in the United States Could Generate Substantial Savings to Society. <b>2015</b> , 41, 341-50	8
709	Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center. <b>2015</b> , 163, 280-90	2
708	Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. <b>2015</b> , 163, 417-26	15
707	A Cost Analysis of the American Board of Internal Medicine's Maintenance-of-Certification Program. <b>2015</b> , 163, 401-8	28
706	Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial. <b>2015</b> , 43, 260-78	28
705	Pharmacological and psychosocial interventions for night eating syndrome in adults. <b>2015</b> ,	1
704	Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment. <b>2015</b> , 173, 1365-6	3
703	Nationwide expansion of a financial incentive program on fruit and vegetable purchases among Supplemental Nutrition Assistance Program participants: A cost-effectiveness analysis. <b>2015</b> , 147, 80-8	20
702	A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. <b>2015</b> , 15, 1201	12
701	Targeting an alcohol intervention cost-effectively to persons living with HIV/AIDS in East Africa. <b>2015</b> , 39, 2179-88	6
700	Cost-effectiveness of pediatric heart transplantation across a positive crossmatch for high waitlist urgency candidates. <b>2015</b> , 15, 2978-85	5
699	Cost-Effectiveness of Diagnostic Strategies for Suspected Scaphoid Fractures. <b>2015</b> , 29, e245-52	27
698	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. <b>2015</b> , 25, 609-17	10
697	Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. <b>2015</b> , 4,	7
696	Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever. <b>2015</b> , 26, 403-7	2

695	Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. <b>2015</b> , 29, 1247-59	23
694	Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. <b>2015</b> , 10, e0127213	18
693	The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. <b>2015</b> , 12, e1001860	51
692	Cost-effectiveness of proton beam therapy for intraocular melanoma. <b>2015</b> , 10, e0127814	16
691	Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. <b>2015</b> , 10, e0142550	5
690	Economic and epidemiological impact of early antiretroviral therapy initiation in India. <b>2015</b> , 18, 20217	9
689	Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. <b>2015</b> , 125, 338-345	76
688	Cost-effective analysis of unilateral vestibular weakness investigation. <b>2015</b> , 36, 277-81	13
687	Quality of life and its association with direct medical costs for COPD in urban China. <b>2015</b> , 13, 57	25
686	The cost-effectiveness of surgical treatment of medial unicompartamental knee osteoarthritis in younger patients: a computer model-based evaluation. <b>2015</b> , 97, 807-17	39
685	Can The EQ-5D Detect Meaningful Change? A Systematic Review. <b>2015</b> , 33, 1137-54	129
684	Sustainability of behavioral interventions: beyond cost-effectiveness analysis. <b>2015</b> , 22, 425-33	53
683	Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the \$50,000 per QALY Threshold. <b>2015</b> , 30, 1118-20	40
682	The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis. <b>2015</b> , 162, 474-84	49
681	Prospective Cohort Study of Hospital Palliative Care Teams for Inpatients With Advanced Cancer: Earlier Consultation Is Associated With Larger Cost-Saving Effect. <b>2015</b> , 33, 2745-52	158
680	EAO consensus conference: economic evaluation of implant-supported prostheses. <b>2015</b> , 26 Suppl 11, 57-63	30
679	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <b>2015</b> , 15, 931-40	16
678	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. <b>2015</b> , 101, 1980-8	11

677	Different Imaging Strategies in Patients With Possible Basilar Artery Occlusion: Cost-Effectiveness Analysis. <b>2015</b> , 46, 1840-9	5
676	Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review. <b>2015</b> , 43, 1530-7	43
675	A decade of investment in infection prevention: a cost-effectiveness analysis. <b>2015</b> , 43, 4-9	56
674	Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients. <b>2015</b> , 274, 455-63	11
673	The clinical role and cost-effectiveness of long-acting antiretroviral therapy. <b>2015</b> , 60, 1102-10	32
672	Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany. <b>2015</b> , 109, 632-41	16
671	Updating the assignment of levels of evidence. <b>2015</b> , 97, 1-2	150
670	Health Aid Is Allocated Efficiently, But Not Optimally: Insights From A Review Of Cost-Effectiveness Studies. <b>2015</b> , 34, 1188-95	7
669	The doses of 10 µg should replace the doses of 5 µg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. <b>2015</b> , 33, 3731-8	14
668	Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. <b>2015</b> , 70, 409-14	15
667	An Introduction to Clinical Significance in Orthopaedic Outcomes Research. <b>2015</b> , 3,	18
666	Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. <b>2015</b> , 33, 2537-44	12
665	Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. <b>2015</b> , 121, 1088-97	35
664	Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. <b>2015</b> , 149, 130-8	91
663	Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. <b>2015</b> , 33, 1467-74	46
662	Cost-effectiveness of the evaluation of a suspicious biliary stricture. <b>2015</b> , 195, 52-60	5
661	A systematic review of utilities in hand surgery literature. <b>2015</b> , 40, 997-1005	11
660	Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation. <b>2015</b> , 12, 1565-73	28

659	Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. <b>2015</b> , 29, 51-63	9
658	Strengthening tuberculosis control overseas: who benefits?. <b>2015</b> , 18, 180-8	7
657	Applying evidence from economic evaluations to translate cancer survivorship research into care. <b>2015</b> , 9, 560-6	4
656	Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana. <b>2015</b> , 15, 130	14
655	G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study. <b>2015</b> , 14, 126	14
654	Do chronic disease patients value generic health states differently from individuals with no chronic disease? A case of a multicultural Asian population. <b>2015</b> , 13, 8	9
653	Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. <b>2015</b> , 13, 14	74
652	Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trial. <b>2015</b> , 16, 97	7
651	Determining the Ideal Strategy for Ventilator-associated Pneumonia Prevention. Cost-Benefit Analysis. <b>2015</b> , 192, 57-63	50
650	The Cost-Utility of Total Hip Arthroplasty: Earlier Intervention, Improved Economics. <b>2015</b> , 30, 945-9	32
649	Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. <b>2015</b> , 192, 229-37	21
648	The 2-year cost-effectiveness of 3 options to treat lumbar spinal stenosis patients. <b>2015</b> , 15, 107-16	25
647	A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. <b>2015</b> , 13, 493-506	8
646	OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis. <b>2015</b> , 23, 677-85	19
645	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. <b>2015</b> , 94 Suppl 2, S249-57	34
644	Saving lives and saving money: hospital-based violence intervention is cost-effective. <b>2015</b> , 78, 252-7; discussion 257-8	61
643	Cost-utility analyses in spine care: a qualitative and systematic review. <b>2015</b> , 40, 31-40	21
642	Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. <b>2015</b> , 45, 3613-23	45

641	Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. <b>2015</b> , 18, 930-43	11
640	Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. <b>2015</b> , 34, 1538-45	29
639	Cost-effectiveness of antibiotic prophylaxis for dental patients with prosthetic joints: Comparisons of antibiotic regimens for patients with total hip arthroplasty. <b>2015</b> , 146, 830-9	14
638	A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. <b>2015</b> , 173, 367-75	50
637	Is there an economic case for investing in nursing care--what does the literature tell us?. <b>2015</b> , 71, 975-90	27
636	Fundamentals of Clinical Outcomes Assessment for Spinal Disorders: Clinical Outcome Instruments and Applications. <b>2015</b> , 5, 329-38	22
635	What Are the Strength of Recommendations and Methodologic Reporting in Health Economic Studies in Orthopaedic Surgery?. <b>2015</b> , 473, 3289-96	8
634	A Systematic Review on the Cost-Effectiveness of Genetic and Electrocardiogram Testing for Long QT Syndrome in Infants and Young Adults. <b>2015</b> , 18, 700-8	8
633	Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis. <b>2015</b> , 277, 763-72	17
632	Dollars and sense. <b>2015</b> , 43, 1313-5	1
631	Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. <b>2015</b> , 16, 1089-100	11
630	Reverse shoulder arthroplasty for massive rotator cuff tear: risk factors for poor functional improvement. <b>2015</b> , 24, 1698-706	78
629	Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. <b>2015</b> , 60, 3743-55	12
628	Dental attendance among low-income women and their children following a brief motivational counseling intervention: A community randomized trial. <b>2015</b> , 144, 9-18	11
627	Cost-utility analysis of the use of prophylactic mesh augmentation compared with primary fascial suture repair in patients at high risk for incisional hernia. <b>2015</b> , 158, 700-11	33
626	Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. <b>2015</b> , 66, 2728-2739	64
625	Cost-effectiveness analysis of the diagnosis of meniscus tears. <b>2015</b> , 43, 128-37	28
624	Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. <b>2015</b> , 33, 271-83	14



623	The opportunity costs of informal elder-care in the United States: new estimates from the American Time Use Survey. <b>2015</b> , 50, 871-82	147
622	Postoperative nausea and vomiting management: cost-effectiveness and patient outcome. 146-155	
621	Returns to Society from Investment in Cancer Research and Development. <b>2016</b> , 19, 71-86	3
620	Cost-Effectiveness of Genetic Testing for Monogenic Diabetes. <b>2016</b> , 389-396	
619	Medical costs and quality-adjusted life years associated with smoking: a systematic review. <b>2016</b> , 16, 646	13
618	Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam. <b>2016</b> , 16, 777	11
617	Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. <b>2016</b> , 13, e1001975	29
616	Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. <b>2016</b> , 11, e0146003	45
615	Cost-effective Decisions in Detecting Silent Common Bile Duct Gallstones During Laparoscopic Cholecystectomy. <b>2016</b> , 263, 1164-72	11
614	Diagnostic Imaging Strategies for Occult Hip Fractures: A Decision and Cost-Effectiveness Analysis. <b>2016</b> , 23, 1161-1169	11
613	A Cost-Utility Assessment of Mesh Selection in Clean-Contaminated Ventral Hernia Repair. <b>2016</b> , 137, 647-659	41
612	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <b>2016</b> , 36, 488-95	13
611	Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. <b>2016</b> , 71, 146-54	8
610	Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis. <b>2016</b> , 54, 474-82	1
609	Cost-effectiveness Analysis of Follow-up Strategies for Thunderclap Headache Patients With Negative Noncontrast CT. <b>2016</b> , 23, 243-50	14
608	Cost-effectiveness of the Cardiac Component of the Focused Assessment of Sonography in Trauma Examination in Blunt Trauma. <b>2016</b> , 23, 415-23	10
607	Cost-Effectiveness of Osteoporosis Screening Strategies for Men. <b>2016</b> , 31, 1189-99	16
606	The Cost-effectiveness of Varicella Zoster Virus Vaccination Considering Late Onset Asthma. <b>2016</b> , 35, e275-84	2

605	Reply: Lifetime Costs of Prophylactic Mastectomies and Reconstruction versus Surveillance. <b>2016</b> , 138, 152e-153e	
604	A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. <b>2016</b> , 122, 1483-501	126
603	Using Length of Stay to Control for Unobserved Heterogeneity When Estimating Treatment Effect on Hospital Costs with Observational Data: Issues of Reliability, Robustness, and Usefulness. <b>2016</b> , 51, 2020-43	21
602	Cost Utility Analysis of the Cervical Artificial Disc vs Fusion for the Treatment of 2-Level Symptomatic Degenerative Disc Disease: 5-Year Follow-up. <b>2016</b> , 79, 135-45	29
601	A View from the Bridge: Health Economic Evaluation - A Value-Based Framework?. <b>2016</b> , 25, 1499-1502	8
600	Guidelines for reporting health economic research. <b>2016</b> , 98-B, 147-51	9
599	Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. <b>2016</b> , 79, 418-25	13
598	Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. <b>2016</b> , 16, 251	3
597	Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries. <b>2016</b> , 10, 1-6	12
596	Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. <b>2016</b> , 17, 701-13	20
595	Designing Radiology Outcomes Studies-Essential Principles. <b>2016</b> , 23, 898-904	3
594	Endoscopic resection is cost-effective compared with laparoscopic resection in the management of complex colon polyps: an economic analysis. <b>2016</b> , 83, 1248-57	68
593	A Primer on Health Economic Evaluations in Thoracic Oncology. <b>2016</b> , 11, 1224-1232	1
592	Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population. <b>2016</b> , 9, 67-71	6
591	Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. <b>2016</b> , 3, e140-6	31
590	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. <b>2016</b> , 19, 795-805	16
589	Can Robot-Assisted Unicompartmental Knee Arthroplasty Be Cost-Effective? A Markov Decision Analysis. <b>2016</b> , 31, 759-65	94
588	Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. <b>2016</b> , 75, 1006-1015	8

587	Targeting Health Behaviors to Reduce Health Care Costs in Pediatric Psychology: Descriptive Review and Recommendations. <b>2016</b> , 41, 835-48	12
586	Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. <b>2016</b> , 63, 79-88	14
585	The accuracy and cost-effectiveness of strategies used to identify peripheral artery disease among patients with diabetic foot ulcers. <b>2016</b> , 64, 1682-1690.e3	23
584	Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. <b>2016</b> , 19, 964-975	18
583	Cost Effectiveness of Implantable Cardiac Monitor-Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study. <b>2016</b> , 27, 1304-1311	8
582	Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?. <b>2016</b> , 14, 245-52	19
581	Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective. <b>2016</b> , 47, 2797-2804	49
580	Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. <b>2016</b> , 44, 1090-1101	17
579	"America's Healthiest Campus": The OSU Well-Being Strategy Model. <b>2016</b> , 30, TAHP2-4	4
578	Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions. <b>2016</b> , 12, 359-368	9
577	Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. <b>2016</b> , 39, 313-20	64
576	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. <b>2016</b> , 14, 1778-1787.e8	10
575	Risk of bias in model-based economic evaluations: the ECOBIAS checklist. <b>2016</b> , 16, 513-23	24
574	Cost of microbial larviciding for malaria control in rural Tanzania. <b>2016</b> , 21, 1468-1475	13
573	Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features. <b>2016</b> , 23, 3641-3652	28
572	Imaging technology assessment. <b>2016</b> , 1-9	
571	Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. <b>2016</b> , 16, 136	22
570	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. <b>2016</b> , 231-255	

569	Operational Components of Telemedicine Programs for Diabetic Retinopathy. <b>2016</b> , 16, 128	14
568	Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. <b>2016</b> , 4, 996-1003	132
567	Response to "Advancing the Economic Assessment of Microinvasive Glaucoma Surgery". <b>2016</b> , 25, e723-4	
566	Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. <b>2016</b> , 24, 796-804	12
565	Economic evaluation of health promotion for older people-methodological problems and challenges. <b>2016</b> , 16 Suppl 5, 328	15
564	Cost Minimization Analysis of Different Strategies of Management of Clinically Significant Scorpion Envenomation Among Pediatric Patients. <b>2016</b> , 32, 856-862	2
563	Cost effectiveness of meniscal allograft for torn discoid lateral meniscus in young women. <b>2016</b> , 44, 278-82	8
562	Cost-Effectiveness of Field Trauma Triage among Injured Adults Served by Emergency Medical Services. <b>2016</b> , 222, 1125-37	15
561	Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs. <b>2016</b> , 28, 1199-204	16
560	At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). <b>2016</b> , 31, 1061-7	12
559	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. <b>2016</b> , 9,	10
558	Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007. <b>2016</b> , 54, 380-5	10
557	Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. <b>2016</b> , 151, 427-439.e6	75
556	Long-term consequences of ovarian ablation for premenopausal breast cancer. <b>2016</b> , 157, 565-73	8
555	Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. <b>2016</b> , 14, 1445-1451.e8	57
554	Cost-effectiveness of Wisconsin TEAM model for improving adherence and hypertension control in black patients. <b>2016</b> , 56, 389-96	9
553	Yoga versus education for Veterans with chronic low back pain: study protocol for a randomized controlled trial. <b>2016</b> , 17, 224	12
552	The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. <b>2016</b> , 44, 1771-80	17

551	Cost-effectiveness of motivational intervention with significant others for patients with alcohol misuse. <b>2016</b> , 111, 832-9	8
550	Cost-effectiveness of transoral robotic surgery versus (chemo)radiotherapy for early T classification oropharyngeal carcinoma: A cost-utility analysis. <b>2016</b> , 38, 589-600	64
549	Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. <b>2016</b> , 67, 29-38	99
548	Cost-Effectiveness of Bariatric Surgery Prior to Total Knee Arthroplasty in the Morbidly Obese: A Computer Model-Based Evaluation. <b>2016</b> , 98, e6	33
547	Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. <b>2016</b> , 19, 445-61	7
546	Early Cholecystectomy for Acute Cholecystitis Offers the Best Outcomes at the Least Cost: A Model-Based Cost-Utility Analysis. <b>2016</b> , 222, 185-94	17
545	Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening. <b>2016</b> , 36, 237-48	5
544	Expanding Health Technology Assessments to Include Effects on the Environment. <b>2016</b> , 19, 249-54	21
543	Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies. <b>2016</b> , 24, 760-8	27
542	Episode of Care Payments in Total Joint Arthroplasty and Cost Minimization Strategies. <b>2016</b> , 12, 91-3	7
541	Early Versus Delayed Surgical Decompression of Spinal Cord after Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. <b>2016</b> , 88, 166-174	31
540	Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <b>2016</b> , 5, 21-31	2
539	Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies. <b>2016</b> , 16, 167-92	1
538	Introduction to Cost Analysis in IR: Challenges and Opportunities. <b>2016</b> , 27, 539-545.e1	8
537	Modeling and Cost-Effectiveness in HIV Prevention. <b>2016</b> , 13, 64-75	19
536	Radiologist Point-of-Care Clinical Decision Support and Adherence to Guidelines for Incidental Lung Nodules. <b>2016</b> , 13, 156-62	22
535	Arthroplasty for the surgical management of complex proximal humerus fractures in the elderly: a cost-utility analysis. <b>2016</b> , 25, 704-13	19
534	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. <b>2016</b> , 62, 1454-1462	13

533	PCSK9 Inhibitors: A Technology Worth Paying For?. <b>2016</b> , 34, 217-20	14
532	The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. <b>2016</b> , 62, 220-229	60
531	Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma. <b>2016</b> , 53, 194-200	25
530	Median-based incremental cost-effectiveness ratios with censored data. <b>2016</b> , 26, 552-64	3
529	Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis. <b>2016</b> , 37, 330-5	33
528	A model to estimate cost-savings in diabetic foot ulcer prevention efforts. <b>2017</b> , 31, 700-707	20
527	Multivariable Regression Model of the EuroQol 5-Dimension Questionnaire in Patients Seeking Outpatient Low Vision Rehabilitation. <b>2017</b> , 24, 174-180	0
526	Analysis of the Association of Clubhouse Membership with Overall Costs of Care for Mental Health Treatment. <b>2017</b> , 53, 102-106	30
525	Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage. <b>2017</b> , 38, 462-468	8
524	Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. <b>2017</b> , 6, 97-108	6
523	The cost-effectiveness of bike lanes in New York City. <b>2017</b> , 23, 239-243	28
522	Impact Of The YMCA Of The USA Diabetes Prevention Program On Medicare Spending And Utilization. <b>2017</b> , 36, 417-424	34
521	Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. <b>2017</b> , 75, 204-212	17
520	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <b>2017</b> , 15, 657-667	9
519	Weight-loss and exercise for communities with arthritis in North Carolina (we-can): design and rationale of a pragmatic, assessor-blinded, randomized controlled trial. <b>2017</b> , 18, 91	9
518	Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study. <b>2017</b> , 2, e133-e140	29
517	Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. <b>2017</b> , 20, 723-731	8
516	Cost-effectiveness of Diagnostic Algorithms for Tuberculosis in Children Less Than 5 Years of Age. <b>2017</b> , 36, 36-43	8

515	Traditional growing rod versus magnetically controlled growing rod for treatment of early onset scoliosis: Cost analysis from implantation till skeletal maturity. <b>2017</b> , 25, 2309499017705022	23
514	Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. <b>2017</b> , 17, 383	31
513	Characterising bias in regulatory risk and decision analysis: An analysis of heuristics applied in health technology appraisal, chemicals regulation, and climate change governance. <b>2017</b> , 105, 20-33	4
512	Bayesian Methods for Calibrating Health Policy Models: A Tutorial. <b>2017</b> , 35, 613-624	29
511	Economic losses and burden of disease by medical conditions in Norway. <b>2017</b> , 121, 691-698	21
510	Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment. <b>2017</b> , 69, 2446-2456	45
509	The Cost-Effectiveness of Dual Mobility Implants for Primary Total Hip Arthroplasty: A Computer-Based Cost-Utility Model. <b>2017</b> , 99, 768-777	38
508	Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents. <b>2017</b> , 45, 2267-2275	18
507	Comparative cost-benefit analysis of tele-homecare for community-dwelling elderly in Japan: Non-Government versus Government Supported Funding Models. <b>2017</b> , 104, 1-9	4
506	Cost-effectiveness of microsurgical reconstruction for head and neck defects after oncologic resection. <b>2017</b> , 39, 541-547	24
505	Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. <b>2017</b> , 41, 1225-1233	12
504	Cost-effectiveness of Virtual Bone Strength Testing in Osteoporosis Screening Programs for Postmenopausal Women in the United States. <b>2017</b> , 285, 506-517	17
503	Understanding United States Investigational Device Exemption Studies-Clinical Relevance and Importance for Healthcare Economics. <b>2017</b> , 80, 840-846	4
502	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <b>2017</b> , 123, 3763-3771	17
501	Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. <b>2017</b> , 43, e36	16
500	Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. <b>2017</b> , 52, e147-e155	54
499	Costs of substance use disorders from claims data for Medicare recipients from a population-based sample. <b>2017</b> , 77, 174-177	2
498	The Cost and Threshold Analysis of Retention in Care (RiC): A Multi-Site National HIV Care Program. <b>2017</b> , 21, 643-649	5

497	State Requirements for Automated External Defibrillators in American Schools: Framing the Debate About Legislative Action. <b>2017</b> , 69, 1735-1743	13
496	Risk-stratified versus Non-Risk-stratified Diagnostic Testing for Management of Suspected Acute Biliary Obstruction: Comparative Effectiveness, Costs, and the Role of MR Cholangiopancreatography. <b>2017</b> , 284, 468-481	8
495	Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Response. <b>2017</b> , 45, NP2-NP4	1
494	Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. <b>2017</b> , 24, 754-768	19
493	CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. <b>2017</b> , 31, 39-49	20
492	Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model. <b>2017</b> , 32, 1370-1377	2
491	Economic Evaluations Comparing a Trial of Labor with an Elective Repeat Cesarean Delivery: A Systematic Review. <b>2017</b> , 20, 163-173	10
490	Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). <b>2017</b> , 48, 379-387	80
489	Cost-Effectiveness of Arthroscopic Rotator Cuff Repair Versus Reverse Total Shoulder Arthroplasty for the Treatment of Massive Rotator Cuff Tears in Patients With Pseudoparalysis and Nonarthritic Shoulders. <b>2017</b> , 33, 716-725	24
488	A Tale of Two Health-Care Systems: Cost-Utility Analysis of Open Carpal Tunnel Release in Canada and the United States. <b>2017</b> , 25, 7-13	11
487	Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. <b>2017</b> , 196, e15-e29	57
486	Cost-Effectiveness of a Clinical Childhood Obesity Intervention. <b>2017</b> , 140,	12
485	Societal Costs of Micronutrient Deficiencies in 6- to 59-month-old Children in Pakistan. <b>2017</b> , 38, 485-500	9
484	Analyzing cost-effectiveness of neural-monitoring in recurrent laryngeal nerve recovery course in thyroid surgery. <b>2017</b> , 48, 180-188	12
483	A Fresh Perspective on a Familiar Problem: Examining Disparities in Knee Osteoarthritis Using a Markov Model. <b>2017</b> , 55, 993-1000	12
482	Early appendectomy reduces costs in children with perforated appendicitis. <b>2017</b> , 220, 119-124	10
481	Cost-Effectiveness of Treatment for Bipolar Disorders. <b>2017</b> , 299-311	1
480	The Health Economics of the spinal cord injury or disease among veterans of war: A systematic review. <b>2017</b> , 40, 649-664	11



479	Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?. <b>2017</b> , 20, 894-901	5
478	Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. <b>2017</b> , 40, 789-796	4
477	The Burden of Retinal Venous Occlusion: An Assessment of Fellow Eyes in 1000 Cases. <b>2017</b> , 1, 404-412	10
476	Benchmarks for Reducing Emergency Department Visits and Hospitalizations Through Community Health Workers Integrated Into Primary Care: A Cost-Benefit Analysis. <b>2017</b> , 55, 140-147	10
475	Polypille in der Sekundärprävention des Herzinfarktes. <b>2017</b> , 11, 473-479	1
474	School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program. <b>2017</b> , 52 Suppl 2, 2307-2330	2
473	Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. <b>2017</b> , 27, 397-421	13
472	Borrow or Serve? An Economic Analysis of Options for Financing a Medical School Education. <b>2017</b> , 92, 966-975	23
471	Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. <b>2017</b> , 20, 1024-1038	5
470	Imaging Strategies for Suspected Acute Cranial Shunt Failure: A Cost-Effectiveness Analysis. <b>2017</b> , 140,	20
469	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. <b>2017</b> , 35, 989-1006	8
468	Cost-Effectiveness Analyses in Orthopaedic Surgery: Raising the Bar. <b>2017</b> , 99, e71	6
467	Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data. <b>2017</b> , 15, 597-614	3
466	Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?. <b>2017</b> , 35, 859-866	24
465	Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. <b>2017</b> , 40, e65-e76	19
464	Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. <b>2017</b> , 17, 225	18
463	The impact of integrated prevention and treatment on child malnutrition and health: the PROMIS project, a randomized control trial in Burkina Faso and Mali. <b>2017</b> , 17, 237	8
462	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. <b>2017</b> , 123, 3725-3731	51

461	A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. <b>2017</b> , 189, 54-60.e3	15
460	Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. <b>2017</b> , 13, 533-542	15
459	Many Miles to Go: A Systematic Review of the State of Cost-Utility Analyses in Brazil. <b>2017</b> , 15, 163-172	2
458	The cost-effectiveness of nonoperative management versus laparoscopic appendectomy for the treatment of acute, uncomplicated appendicitis in children. <b>2017</b> , 52, 1135-1140	13
457	Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. <b>2017</b> , 21, 903-914	35
456	A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. <b>2017</b> , 28, 643-652	9
455	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. <b>2017</b> , 65, 122-133	65
454	Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy. <b>2017</b> , 35, 163-176	5
453	Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation. <b>2017</b> , 17, 15-25	35
452	The true cost of thyroid surgery determined by a micro-costing approach. <b>2017</b> , 55, 519-529	10
451	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. <b>2017</b> , 20, 140-150	35
450	Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. <b>2017</b> , 45, 210-217	39
449	The Cost-Effectiveness of Anterior Cruciate Ligament Reconstruction in Competitive Athletes. <b>2017</b> , 45, 23-33	21
448	Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. <b>2017</b> , 85, 773-781.e10	21
447	Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. <b>2017</b> , 28, 585-595	20
446	Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States. <b>2017</b> , 21, 619-625	8
445	Health State Utility Values for Age-Related Macular Degeneration: Review and Advice. <b>2017</b> , 15, 23-32	7
444	Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. <b>2017</b> , 96, e9113	9

443	Advanced Imaging Adds Little Value in the Diagnosis of Femoroacetabular Impingement Syndrome. <b>2017</b> , 99, e133	11
442	Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. <b>2017</b> , 8, 614	5
441	Lessons Learned From Cohort Studies, and Hospital-Based Studies and Their Implications in Precision Medicine. <b>2017</b> , 187-207	1
440	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <b>2017</b> , 14, e1002397	48
439	Cost-effectiveness of a national enterovirus 71 vaccination program in China. <b>2017</b> , 11, e0005899	14
438	The cost determinants of routine infant immunization services: a meta-regression analysis of six country studies. <b>2017</b> , 15, 178	12
437	Investigating the 7-Year Cost-Effectiveness of Single-Level Cervical Disc Replacement Compared to Anterior Cervical Discectomy and Fusion. <b>2018</b> , 8, 32-39	10
436	Robotic Versus Video-Assisted Thoracoscopic Lung Resection During Early Program Development. <b>2018</b> , 105, 1050-1057	13
435	A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation. <b>2018</b> , 21, 185-192	2
434	People in states worse than dead according to the EQ-5D UK value set: would they rather be dead?. <b>2018</b> , 27, 1827-1833	13
433	Are people living with HIV less productive at work?. <b>2018</b> , 30, 1265-1272	8
432	mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. <b>2018</b> , 3, e000328	12
431	The Seven-Year Cost-Effectiveness of Anterior Cervical Discectomy and Fusion Versus Cervical Disc Arthroplasty: A Markov Analysis. <b>2018</b> , 43, 1543-1551	20
430	Cost-utility analysis in orthopaedic trauma; what pays? A systematic review. <b>2018</b> , 49, 575-584	6
429	Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma. <b>2018</b> , 110, e496-e503	12
428	Cost-effectiveness of the non-laboratory based Framingham algorithm in primary prevention of cardiovascular disease: A simulated analysis of a cohort of African American adults. <b>2018</b> , 111, 415-422	5
427	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. <b>2018</b> , 27, 707-716	19
426	The Economic Burden of Asthma in the United States, 2008-2013. <b>2018</b> , 15, 348-356	339

425	Cost-Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program. <b>2018</b> , 22, 3734-3741	8
424	Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. <b>2018</b> , 98, 16-27	16
423	Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations. <b>2018</b> , 20, 1131-1144	37
422	A Palliative Radiation Oncology Consult Service Reduces Total Costs During Hospitalization. <b>2018</b> , 55, 1452-1458	11
421	Effects of Arthroscopy for Femoroacetabular Impingement Syndrome on Quality of Life and Economic Outcomes. <b>2018</b> , 46, 1205-1213	28
420	Cost-Effectiveness Research in Anesthesiology. <b>2018</b> , 127, 1196-1201	4
419	Systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. <b>2018</b> , 14, 1041-1059	9
418	Cost-effectiveness analysis of intensive hypertension control in China. <b>2018</b> , 111, 110-114	17
417	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. <b>2018</b> , 21, 525-536	14
416	Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. <b>2018</b> , 13, 75-85	2
415	MRI surveillance of vestibular schwannomas without contrast enhancement: Clinical and economic evaluation. <b>2018</b> , 128, 202-209	28
414	Definition of a Geriatric Depression Scale cutoff based upon quality of life: a population-based study. <b>2018</b> , 33, e58-e64	13
413	Electromagnetic-guided placement of nasoduodenal feeding tubes versus endoscopic placement: a randomized, multicenter trial. <b>2018</b> , 87, 110-118	7
412	A systematic review of the cost and economic outcomes of home enteral nutrition. <b>2018</b> , 37, 429-442	19
411	Preference Heterogeneity in the Structural Estimation of Efficient Pigovian Incentives for Insecticide Spraying to Reduce Malaria. <b>2018</b> , 70, 169-190	1
410	Estimating the cost of school sealant programs with minimal data. <b>2018</b> , 78, 17-24	7
409	Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. <b>2018</b> , 27, 656-665	8
408	Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. <b>2018</b> , 32, 210-215	18

407	The impact of urban speed reduction programmes on health system cost and utilities. <b>2018</b> , 24, 262-266	6
406	Projecting the impact of a nationwide school plain water access intervention on childhood obesity: a cost-benefit analysis. <b>2018</b> , 13, 715-723	5
405	Approach to asymptomatic paraesophageal hernia: watchful waiting or elective laparoscopic hernia repair?. <b>2018</b> , 32, 864-871	15
404	Cost-effectiveness of Magnetic Resonance Imaging in Cervical Spine Clearance of Neurologically Intact Patients With Blunt Trauma. <b>2018</b> , 71, 64-73	19
403	Is Two-level Cervical Disc Replacement More Cost-effective Than Anterior Cervical Discectomy and Fusion at 7 Years?. <b>2018</b> , 43, 610-616	10
402	Using tele-emergency to avoid patient transfers in rural emergency departments: An assessment of costs and benefits. <b>2018</b> , 24, 193-201	20
401	A Systematic Review of Cost-of-Illness Studies of Multimorbidity. <b>2018</b> , 16, 15-29	66
400	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. <b>2018</b> , 16, 392-400.e7	14
399	Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. <b>2018</b> , 128, 328-337	28
398	Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion. <b>2018</b> , 16, 123-132	5
397	Financial Aspects of Inpatient Palliative Care. <b>2018</b> , 1-10	
396	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. <b>2018</b> , 36, 3192-3202	71
395	Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology. <b>2018</b> , 38, 850-860	6
394	Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. <b>2018</b> , JCO1800122	23
393	Design and Rationale of the Cognitive Intervention to Improve Memory in Heart Failure Patients Study. <b>2018</b> , 33, 344-355	1
392	Cost-utility studies in upper limb orthopaedic surgery: a systematic review of published literature. <b>2018</b> , 100-B, 1416-1423	4
391	Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data. <b>2018</b> , 29, 1705-1712	9
390	Economic Impact of Financial Incentives and Mailing Nicotine Patches to Help Medicaid Smokers Quit Smoking: A Cost-Benefit Analysis. <b>2018</b> , 55, S148-S158	2

389	Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. <b>2018</b> , 151, 506-512	3
388	Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. <b>2018</b> , 19, 597-605	7
387	Early Childhood Inpatient Costs of Critical Congenital Heart Disease. <b>2018</b> , 203, 371-379.e7	10
386	Cutting-edge evidence of adjuvant treatments for gastric cancer. <b>2018</b> , 12, 1109-1122	0
385	Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model. <b>2018</b> , 100, 1653-1660	14
384	Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. <b>2018</b> , 1, e182008	5
383	Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. <b>2018</b> , 43, 758-768	5
382	Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea. <b>2018</b> , 16, 527-535	3
381	Electronic Version of the EQ-5D Quality-of-Life Questionnaire: Adaptation to a Brazilian Population Sample. <b>2018</b> , 17, 88-93	8
380	Bladder Extirpation vs Preservation: The Treatment Debate. <b>2018</b> , 153, 889-890	1
379	Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. <b>2018</b> , 63, 2094-2104	19
378	Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy. <b>2018</b> , 18, 487-503	1
377	Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. <b>2018</b> , 155, 648-660	63
376	Cost of HPV screening at community health campaigns (CHCs) and health clinics in rural Kenya. <b>2018</b> , 18, 378	4
375	Biostatistics in Cardiovascular Research with Emphasis on Sex-Related Aspects. <b>2018</b> , 1065, 71-92	
374	Cost-effectiveness analysis of magnetic resonance imaging-conditional pacemaker implantation: Insights from a multicenter study and implications in the current era. <b>2018</b> , 15, 1690-1697	3
373	Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. <b>2018</b> , 273, 74-79	5
372	Statistical primer: a cost-effectiveness analysis. <b>2018</b> , 54, 209-213	3

371	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. <b>2018</b> , 62, 673-681	19
370	Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. <b>2018</b> , 113, 1836-1847	10
369	Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. <b>2019</b> , 51, 1731-1737	2
368	Routine fixation of displaced midshaft clavicle fractures is not cost-effective: a cost analysis from a randomized controlled trial. <b>2019</b> , 101-B, 995-1001	10
367	A New Method for Model-Based Health Economic Evaluation Utilizing and Extending Moment-Generating Functions. <b>2019</b> , 39, 523-539	2
366	Convergent validity of the EQ-5D-3L in a randomized-controlled trial of the Housing First model. <b>2019</b> , 19, 482	2
365	Patient Perception and Cost-Effectiveness of a Patient Navigation Program to Improve Breast Cancer Screening for Hispanic Women. <b>2019</b> , 3, 280-286	3
364	Cost-effectiveness and satisfaction following arthroscopic rotator cuff repair: does age matter?. <b>2019</b> , 101-B, 860-866	16
363	Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. <b>2019</b> , 14, e0218890	19
362	A systematic review of the development and testing of additional dimensions for the EQ-5D descriptive system. <b>2019</b> , 19, 431-443	2
361	Economic Value in Minimally Invasive Spine Surgery. <b>2019</b> , 12, 300-304	6
360	Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View. <b>2019</b> , 19, 138-144	
359	On discount rates for economic evaluations in global health. <b>2020</b> , 35, 107-114	31
358	Rationale, design, and baseline data for a multicenter randomized clinical trial comparing depression screening strategies after acute coronary syndrome: The comparison of depression identification after acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. <b>2019</b> , 34, 105823	5
357	Cost-effectiveness of smoking cessation programs for hospitalized patients: a systematic review. <b>2019</b> , 20, 1409-1424	4
356	Racial/ethnic disparities in disease burden and costs related to exposure to endocrine-disrupting chemicals in the United States: an exploratory analysis. <b>2019</b> , 108, 34-43	25
355	Cost Effectiveness of Assessing Ultrasound Plaque Characteristics to Risk Stratify Asymptomatic Patients With Carotid Stenosis. <b>2019</b> , 8, e012739	2
354	Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China. <b>2019</b> , 37, 5868-5876	3



353	Treatment sequences for advanced renal cell carcinoma: A health economic assessment. <b>2019</b> , 14, e0215761	13
352	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. <b>2019</b> , 14, e0220234	18
351	A randomized controlled trial of a smoking cessation self-help intervention for Spanish-speaking Hispanic/Latinx smokers: Study design and baseline characteristics. <b>2019</b> , 85, 105836	1
350	The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. <b>2019</b> , 3, 311-319	5
349	Le Fort III in Syndromic Craniosynostosis: Cost Comparison of Distraction Osteogenesis Versus Single-Stage Internal Fixation Techniques. <b>2019</b> , 27, 125-129	2
348	Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. <b>2019</b> , 22, 1243-1252	7
347	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data. <b>2019</b> , 8, e011577	16
346	Review article: A primer for clinical researchers in the emergency department: Part X. Understanding economic evaluation alongside emergency medicine research. <b>2019</b> , 31, 710-714	3
345	Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. <b>2019</b> , 14, e0217778	8
344	Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. <b>2019</b> , 60, 1472-1481	9
343	Health-related quality of life in adolescents and young adults with cancer - Including a focus on economic evaluation. <b>2019</b> , 66, e27808	1
342	Frailty predicts increased costs in emergent general surgery patients: A prospective cohort cost analysis. <b>2019</b> , 166, 82-87	17
341	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <b>2019</b> , 14, e0205633	21
340	Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria. <b>2019</b> , 52, 807-815	6
339	Evaluation of an Intervention to Reduce Low-Value Preoperative Care for Patients Undergoing Cataract Surgery at a Safety-Net Health System. <b>2019</b> , 179, 648-657	13
338	Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. <b>2019</b> , 153, 87-91	3
337	Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis. <b>2019</b> , 212, 830-838	16
336	Assessing the cost of providing a prevention of mother-to-child transmission of HIV/AIDS service in Ethiopia: urban-rural health facilities setting. <b>2019</b> , 19, 148	4



335	Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. <b>2019</b> , 6, ofy353	12
334	MR-Guided Focused Ultrasound Versus Radiofrequency Capsulotomy for Treatment-Refractory Obsessive-Compulsive Disorder: A Cost-Effectiveness Threshold Analysis. <b>2019</b> , 13, 66	11
333	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. <b>2019</b> , 2, e190047	24
332	Clinical and Economic Benefits of Stent Grafts in Dysfunctional and Thrombosed Hemodialysis Access Graft Circuits in the REVISE Randomized Trial. <b>2019</b> , 30, 203-211.e4	10
331	An Introduction to Economic Analysis of Food Security and Nutrition Interventions. <b>2019</b> , 119, 856-864	4
330	Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening. <b>2019</b> , 7, 105-113	8
329	Cost-effectiveness analysis of prognostic-based depression monitoring. <b>2019</b> , 9, 41-54	5
328	Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. <b>2019</b> , 21, 1948-1957	30
327	Robot-assisted unicompartmental knee arthroplasty for patients with isolated medial compartment osteoarthritis is cost-effective: a markov decision analysis. <b>2019</b> , 101-B, 1063-1070	30
326	Cost-Effectiveness Analysis for Cardiovascular Magnetic Resonance Imaging. <b>2019</b> , 568-573.e1	0
325	Immediate Reconstruction of Oncologic Spinal Wounds Is Cost-Effective Compared with Conventional Primary Wound Closure. <b>2019</b> , 144, 1182-1195	3
324	Indirect Cost of Traumatic Brachial Plexus Injuries in the United States. <b>2019</b> , 101, e80	14
323	A General Population Utility Valuation Study for Metastatic Epidural Spinal Cord Compression Health States. <b>2019</b> , 44, 943-950	1
322	The Economic Impact of Flexor Tendon Lacerations of the Hand in the United States. <b>2019</b> , 83, 419-423	4
321	Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB: methodology and lessons learned. <b>2019</b> , 18, 263-276	9
320	Cost-Effectiveness Studies in the ICU: A Systematic Review. <b>2019</b> , 47, 1011-1017	10
319	Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis. <b>2019</b> , 48, 526-536	25
318	Patient-Level Value Analysis: An Innovative Approach to Optimize Care Delivery. <b>2019</b> , 33 Suppl 7, S49-S52	5

317	A Simplified Cost-Utility Analysis of Inpatient Flap Monitoring after Microsurgical Breast Reconstruction and Implications for Hospital Length of Stay. <b>2019</b> , 144, 540e-549e	8
316	Development of 3D-printed myoelectric hand orthosis for patients with spinal cord injury. <b>2019</b> , 16, 162	28
315	Cost-effectiveness analysis of total elbow arthroplasty versus open reduction-internal fixation for distal humeral fractures. <b>2019</b> , 28, 102-111	6
314	Use of Checklists in Reviews of Health Economic Evaluations, 2010 to 2018. <b>2019</b> , 22, 377-382	32
313	Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. <b>2019</b> , 37, 119-130	21
312	Cost-Effectiveness Analysis: An Overview of Key Concepts, Recommendations, Controversies, and Pitfalls. <b>2019</b> , 26, 534-541	6
311	Comparative Cost-Effectiveness of Clinic, Home, or Ambulatory Blood Pressure Measurement for Hypertension Diagnosis in US Adults. <b>2019</b> , 73, 121-131	25
310	Measuring the value of MRI: Comparative effectiveness & outcomes research. <b>2019</b> , 49, e78-e84	4
309	The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities. <b>2019</b> , 3, 197-204	
308	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <b>2019</b> , 125, 278-289	18
307	Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. <b>2019</b> , 56, 309-319	9
306	Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective. <b>2018</b> , 1-10	0
305	Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction. <b>2019</b> , 74, 141-156	23
304	Optimising the cost-effectiveness of speed limit enforcement cameras. <b>2019</b> , 25, 273-277	0
303	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. <b>2019</b> , 19, 211-218	17
302	Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states. <b>2019</b> , 123, 166-172	12
301	Economic evaluation of a supported employment program for veterans with spinal cord injury. <b>2020</b> , 42, 1423-1429	2
300	Cost-efficacy of Knee Cartilage Defect Treatments in the United States. <b>2020</b> , 48, 242-251	22

299	Cost-effectiveness of Operative Versus Non-operative Management of Acute Achilles Tendon Ruptures. <b>2020</b> , 16, 39-45	5
298	A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation. <b>2020</b> , 4, 159-169	4
297	Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. <b>2020</b> , 145, 1367-1377.e4	1
296	Cost-effectiveness of dual-energy CT versus multiphasic single-energy CT and MRI for characterization of incidental indeterminate renal lesions. <b>2020</b> , 45, 1896-1906	6
295	Cost-Effectiveness of Postoperative Drug Rehabilitation for Injection Drug Users. <b>2020</b> , 110, 492-499	3
294	Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. <b>2020</b> , 17, 452-461	4
293	Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. <b>2020</b> , 38, 233-242	8
292	Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial. <b>2020</b> , 180, 206-214	14
291	HEALTHCARE INTERVENTIONS FOR IMPROVING ACCESS. <b>2020</b> , 137-193	
290	Biomarkers in Lung Cancer. <b>2020</b> , 41, 115-127	19
289	Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective. <b>2020</b> , 10, e036517	1
288	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. <b>2020</b> , 23, 1027-1033	3
287	Obstetric Intraoperative Cell Salvage: A Review of an Established Cell Salvage Service With 1170 Reinfused Cases. <b>2020</b> , 40, 77-78	
286	Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. <b>2020</b> , 131, 411-448	146
285	Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. <b>2020</b> , 183, 251-262	1
284	HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications. <b>2020</b> , 26, 1548-1557	
283	Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population. <b>2020</b> , 29, 3407-3417	5
282	Early Economic Analysis of Robotic-Assisted Unicompartmental Knee Arthroplasty May Be Cost Effective in Patients with End-Stage Osteoarthritis. <b>2020</b> ,	2

281	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <b>2020</b> , 18, 240	1
280	Endoscopy for Gastric Cancer Screening Is Cost Effective for Asian Americans in the United States. <b>2020</b> , 18, 3026-3039	13
279	Decision model analyses of upper endoscopy for gastric cancer screening and preneoplasia surveillance: a systematic review. <b>2020</b> , 13, 1756284820941662	12
278	Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies. <b>2020</b> , 23, 1096-1108	2
277	Systematic Review of the Evolution of Health-Economic Evaluation Models of Osteoarthritis. <b>2021</b> , 73, 1617-1627	
276	Cost Considerations for Robotic Surgery. <b>2020</b> , 53, 1131-1138	1
275	A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population. <b>2021</b> , 21, 765-774	2
274	Cost-Effectiveness Analysis of Motion-Preserving Operations for Wrist Arthritis. <b>2020</b> , 146, 588e-598e	1
273	Modelling the cost-effectiveness of total knee arthroplasty: A systematic review. <b>2020</b> , 22, 485-492	3
272	Cost-effectiveness analysis of using the heat and moisture exchangers compared with alternative stoma covers in laryngectomy rehabilitation: US perspective. <b>2020</b> , 42, 3720-3734	3
271	Cost of Increasing Years-of-Life-Gained (YLG) Using Fecal Immunochemical Testing as a Population-Level Screening Model in a Rural Appalachian Population. <b>2021</b> , 37, 576-584	0
270	Cost-effectiveness of a family-based multicomponent outpatient intervention program for children with obesity in Germany. <b>2020</b> , 186, 185-192	1
269	Therapeutic Facet Joint Interventions in the Lumbar Spine: An Economic Value Perspective. <b>2020</b> , 33, 411-417	0
268	Economic Considerations in Infectious Diseases Emergency Response Preparedness: It's All About the Point of View. <b>2021</b> , 72, 148-152	3
267	A scoping review of the rationale and evidence for cost-effectiveness analysis of fenestrated-branched endovascular repair for intact complex aortic aneurysms. <b>2020</b> , 72, 1772-1782	4
266	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. <b>2020</b> , 5, 871-880	10
265	Cost-effectiveness of physiotherapeutic interventions for low back pain: a systematic review. <b>2020</b> , 108, 98-107	3
264	Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. <b>2020</b> , 5, 899-908	27

263	A safe level of alcohol consumption: the right answer demands the right question. <b>2020</b> , 288, 550-559	6
262	Economic Evaluation Studies. <b>2020</b> , 158, S88-S96	3
261	Theoretical bounds on the value of improved health. <b>2020</b> , 72, 102341	4
260	Enhanced recovery following hip and knee arthroplasty: a systematic review of cost-effectiveness evidence. <b>2020</b> , 10, e032204	7
259	Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles. <b>2020</b> , 3, e1919963	1
258	Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children. <b>2020</b> , 17,	0
257	Assessing the cost-effectiveness of home automated external defibrillators for pediatric patients: Getting us closer to the truth. <b>2020</b> , 17, 1335-1336	
256	Robustness of risk-based allocation of resources for disease prevention. <b>2020</b> , 29, 3511-3524	
255	The economics of drug allergy. <b>2020</b> , 20, 395-400	1
254	Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. <b>2020</b> , 26, 879-886	
253	Cost-effectiveness of couples' voluntary HIV counselling and testing in six African countries: a modelling study guided by an HIV prevention cascade framework. <b>2020</b> , 23 Suppl 3, e25522	2
252	The Video intervention to Inspire Treatment Adherence for Life (VITAL Start): protocol for a multisite randomized controlled trial of a brief video-based intervention to improve antiretroviral adherence and retention among HIV-infected pregnant women in Malawi. <b>2020</b> , 21, 207	6
251	Cost-utility analysis comparing surgical and nonsurgical interventions in the treatment of erectile dysfunction. <b>2020</b> , 43, 613-620	0
250	The business case for quality improvement. <b>2020</b> , 40, 972-979	5
249	An Enhanced Approach for Economic Evaluation of Long-Term Benefits of School-Based Health Promotion Programs. <b>2020</b> , 12,	1
248	Appointment reminders to increase uptake of HIV retesting by at-risk individuals: a randomized controlled study in Thailand. <b>2020</b> , 23, e25478	2
247	Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. <b>2020</b> , 112S, 18-27	2
246	Cost-effectiveness of the reverse total shoulder arthroplasty. Does indication affect outcome?. <b>2021</b> , 13, 90-97	2

245	The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface. <b>2021</b> , 72, 939-941	1
244	Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review. <b>2021</b> , 21, 205-220	1
243	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <b>2021</b> , 40, 53-61	16
242	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. <b>2021</b> , 137, 969-976	17
241	Cost-effectiveness analyses in shoulder arthroplasty: a critical review using the Quality of Health Economic Studies (QHES) instrument. <b>2021</b> , 30, 1007-1017	2
240	Cost effectiveness analyses of total hip arthroplasty for hip osteoarthritis: A PRISMA systematic review. <b>2021</b> , 75, e13806	11
239	Health economic evaluation in ophthalmology. <b>2021</b> , 105, 602-607	1
238	Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. <b>2021</b> , 24, 654-664	1
237	Factors affecting development of air ambulance base: A systematic review and thematic analysis. <b>2021</b> , 10, 320	0
236	Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. <b>2021</b> ,	10
235	The economic cost of delirium: A systematic review and quality assessment. <b>2021</b> , 17, 1026-1041	4
234	Economic evaluation of a reduced dosage of ready-to-use therapeutic foods to treat uncomplicated severe acute malnourished children aged 6-59 months in Burkina Faso. <b>2021</b> , 17, e13118	1
233	Association between the appropriateness of surgery, according to appropriate use criteria, and patient-rated outcomes after surgery for lumbar degenerative spondylolisthesis. <b>2021</b> , 30, 907-917	1
232	Plate fixation of midshaft clavicle fractures for delayed union and non-union is a cost-effective intervention but functional deficits persist at long-term follow-up. 175857322199036	
231	Health-Related Quality-of-Life and Cost Utility Analyses in Critical Care: A Systematic Review. <b>2021</b> , 49, 575-588	1
230	Comparison of (Partial) economic evaluations of transforaminal lumbar interbody fusion (TLIF) versus Posterior lumbar interbody fusion (PLIF) in adults with lumbar spondylolisthesis: A systematic review. <b>2021</b> , 16, e0245963	1
229	Economic evaluation of point of care universal newborn screening for glucose-6-Phosphate dehydrogenase deficiency in United States. <b>2021</b> , 1-9	1
228	Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. <b>2021</b> , 13,	2

227	Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map. <b>2021</b> , 1	4
226	Cost-effectiveness analysis of housing first intervention with an independent housing and team support for homeless people with severe mental illness: A Markov model informed by a randomized controlled trial. <b>2021</b> , 272, 113692	1
225	Understanding Health Economics in Spine Surgery. <b>2021</b> , 9,	2
224	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. <b>2021</b> , 4, e214846	16
223	Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada. <b>2021</b> , 5, 491-504	1
222	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <b>2021</b> , 22, 723-733	2
221	Understanding cost-utility analysis studies in the trauma and orthopaedic surgery literature. <b>2021</b> , 6, 305-315	0
220	A Study Comparing Cost-Effectiveness of Combination Therapy for Preventing Opportunistic Infections Among Human Immunodeficiency Virus-Infected Adults on Antiretroviral Therapy. <b>2021</b> , 24, 107-113	1
219	The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study. <b>2021</b> , 161, 367-373	1
218	Rotavirus Vaccination Likely to Be Cost Saving to Society in the United States. <b>2021</b> , 73, 1424-1430	0
217	Cost evaluation of tobacco control interventions in clinical settings: A systematic review. <b>2021</b> , 146, 106469	3
216	Current Orthopaedic Health Economic Literature: Quality Is High but Ethical and Societal Perspectives Are Lacking. <b>2021</b> , 37, 2000-2008	0
215	Cost-effectiveness of open transforaminal lumbar interbody fusion (OTLIF) versus minimally invasive transforaminal lumbar interbody fusion (MITLIF): a systematic review and meta-analysis. <b>2021</b> , 21, 945-954	6
214	Preoperative contingency management intervention for smoking abstinence in cancer patients: trial protocol for a multisite randomised controlled trial. <b>2021</b> , 11, e051226	
213	Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. <b>2021</b> , 4, e2113969	0
212	The Economic Impact of Extensor Tendon Lacerations of the Hand in the United States. <b>2021</b> ,	
211	The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review. <b>2021</b> , 1	0
210	Cost Analyses of Prosthetic Devices: A Systematic Review. <b>2021</b> , 102, 1404-1415.e2	2

209	A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: is existing evidence good enough to support policy decision-making?. <b>2021</b> , 21, 1159-1178	1
208	Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. <b>2022</b> , 31, 72-80	1
207	Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees. <b>2021</b> , 24, 100262	1
206	Accounting for Country- and Time-Specific Values in the Economic Evaluation of Health-Related Projects Relevant to low- and Middle-Income Countries. <b>2021</b> ,	0
205	Costs of Identifying Cases of Syphilis Using Rapid Syphilis Tests in Multiple Nonclinical Settings in the United States. <b>2021</b> , 48, 895-899	0
204	Cost-Effective Analysis of Dual-Energy Computed Tomography for the Diagnosis of Occult Hip Fractures Among Older Adults. <b>2021</b> , 24, 1754-1762	0
203	A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. <b>2021</b> , 127, 4432-4446	2
202	Cost-effectiveness and return on investment of school-based health promotion programmes for chronic disease prevention. <b>2021</b> , 31, 1183-1189	1
201	Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer. <b>2021</b> , 58, 72-79	2
200	Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China. <b>2021</b> , 4, e2121403	1
199	A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. <b>2021</b> , 1	1
198	Cost-effectiveness of risk-stratified endoscopic screening for esophageal cancer in high-risk areas of China: a modeling study. <b>2021</b> ,	0
197	Assessing quality-adjusted years of life lost associated with exclusive cigarette smoking and smokeless tobacco use. <b>2021</b> , 150, 106707	1
196	Planned Evaluation of the Healthy Weight Clinic Pediatric Weight Management and Implementation: Massachusetts-CORD 3.0. <b>2021</b> , 17, S55-S61	0
195	Cost-effectiveness of field trauma triage among injured children transported by emergency medical services. <b>2021</b> , 50, 492-500	
194	Economic Analysis of Perioperative Optimization. <b>2022</b> , 638-644	
193	Pharmacoeconomics. <b>2021</b> , 915-927	
192	Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program. <b>2021</b> , 51, 610-622	2



191	Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain. <b>2020</b> , 3, e2028312	8
190	Adapting Cost Analytic Techniques to Local HIV Prevention Programs. <b>1998</b> , 163-175	1
189	Economics of Hematopoietic Growth Factors. <b>2004</b> , 409-443	5
188	A Markov Decision Process Approach to Estimate the Risk of Obesity Related Cancers. <b>2019</b> , 489-502	1
187	Health Economics in Blood Safety. <b>2019</b> , 53-81	1
186	Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement. <b>2002</b> , 17, 126-133	2
185	Economic Issues and Genomic Medicine. <b>2009</b> , 424-433	2
184	Assessing disease activity and outcome in scleroderma. <b>2011</b> , 1367-1371	3
183	Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes. <b>2020</b> , 13, 1505-1517	24
182	Health and economic consequences of applying the United States' PM automobile emission standards to other nations: a case study of France and Italy. <b>2020</b> , 183, 81-87	4
181	How to use the results of an economic evaluation. <b>1999</b> , 27, 1195-202	32
180	Surviving intensive care. <b>2002</b> , 30, 703-5	16
179	Putting a lid on injury costs: the economic impact of the California motorcycle helmet law. <b>1998</b> , 45, 550-6	32
178	Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. <b>1999</b> , 48, 94-104	24
177	Outcome assessment in cardiac rehabilitation. Health-related quality of life and economic evaluation. <b>1997</b> , 17, 179-94	34
176	Pharmaceuticals--cost or investment? An employer's perspective. <b>2000</b> , 42, 338-51	20
175	Minimally invasive drainage of subcutaneous abscesses reduces hospital cost and length of stay. <b>2013</b> , 106, 689-92	15
174	Mortality and Productivity Losses From Alzheimer Disease Among US Adults Aged 40 to 64 Years, 1999 to 2010. <b>2015</b> , 29, 165-8	10

173	Clinical Impact and Cost-Effectiveness of a 176-Condition Expanded Carrier Screen.	3
172	Cost issues with telepsychiatry in the United States. <b>2004</b> , 1, 6-8	4
171	Health status profile and health-related quality of life of veterans attending an out-patient clinic. <b>2013</b> , 19, 386-92	5
170	Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. <b>2017</b> , 14, e1002225	69
169	Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study. <b>2020</b> , 17, e1003407	6
168	Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. <b>2011</b> , 6, e18391	28
167	A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong. <b>2012</b> , 7, e33123	17
166	Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. <b>2013</b> , 8, e78548	34
165	Validation and calibration of a computer simulation model of pediatric HIV infection. <b>2013</b> , 8, e83389	22
164	A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. <b>2013</b> , 8, e83959	28
163	Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. <b>2014</b> , 9, e110525	19
162	Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis. <b>2015</b> , 10, e0130256	11
161	Factors Associated with Reduced Quality of Life in Polio Survivors in Korea. <b>2015</b> , 10, e0130448	11
160	Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. <b>2016</b> , 11, e0148106	10
159	Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach. <b>2017</b> , 12, e0177848	14
158	The cost of demand creation activities and voluntary medical male circumcision targeting school-going adolescents in KwaZulu-Natal, South Africa. <b>2017</b> , 12, e0179854	7
157	The full benefits of adult pneumococcal vaccination: A systematic review. <b>2017</b> , 12, e0186903	23
156	From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. <b>2020</b> , 15, e0233526	7

155	Diplomacy and Health: The End of the Utilitarian Era. <b>2017</b> , 6, 191-194	3
154	Analyzing the cost of neonatal screening for congenital adrenal hyperplasia. <b>2001</b> , 107, 1238	2
153	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. <b>2017</b> , 91-111	3
152	Economic evaluation in orthopaedics. <b>2003</b> , 85, 129-42	57
151	An Economic Analysis of the Timing of Microsurgical Reconstruction in Brachial Plexus Birth Palsy. <b>2007</b> , 89, 970-978	7
150	Economical analysis on prophylaxis, diagnosis, and treatment of periprosthetic infections. <b>2013</b> , 7, 227-42	15
149	A Checklist for the Conduct, Reporting, and Appraisal of Microcosting Studies in Health Care: Protocol Development. <b>2016</b> , 5, e195	10
148	Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). <b>2019</b> , 8, e9898	4
147	UK DRAFFT: a randomised controlled trial of percutaneous fixation with Kirschner wires versus volar locking-plate fixation in the treatment of adult patients with a dorsally displaced fracture of the distal radius. <b>2015</b> , 19, 1-124, v-vi	55
146	Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea. <b>2019</b> , 60, 1157-1163	2
145	Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices. <b>2014</b> , 20, 10464-9	5
144	Cost-effectiveness of noninvasive ventilation for chronic obstructive pulmonary disease-related respiratory failure in Indian hospitals without ICU facilities. <b>2015</b> , 32, 549-56	13
143	Can early counselling and support for Alzheimer's disease caregivers reduce burden? Study protocol for a multicenter randomized controlled trial. <b>2016</b> , 1, 99	3
142	Value-based medicine: concepts and application. <b>2015</b> , 37, e2015014	45
141	A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn's disease. <b>2014</b> , 06, 107-114	3
140	Techniques for Determining the Treatment Costs of Cervical Cancer: A Systematic Review. <b>2019</b> , 09, 117-128	1
139	The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. <b>2006</b> , 75, 119-30	32
138	Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. <b>2006</b> , 75, 131-43	29

137	Defining the Value of Spine Care. <b>2013</b> , 21, 419-426	33
136	Cost effectiveness of intensive care in a low resource setting: A prospective cohort of medical critically ill patients. <b>2016</b> , 5, 150-64	17
135	The cost-effectiveness of immunohistochemistry. <b>2000</b> , 124, 1185-91	33
134	The quality of reporting in published cost-utility analyses, 1976-1997. <b>2000</b> , 132, 964-72	141
133	Cost-Effectiveness Analyses on Various Models of The Red Light, Purple Light Self-Regulation Intervention for Young Children. <b>2021</b> , 12, 711578	0
132	The benefit of an ambulant psychiatric rehabilitation program in Vienna, Austria: an uncontrolled repeated measures study. <b>2021</b> , 1-30	1
131	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. <b>2021</b> ,	4
130	Combining econometric analysis and simulation modeling to evaluate Population-Based health policies for chronic disease prevention and control.. <b>2021</b> , 24, 101586	
129	Surgeons and Health Services Research. <b>2001</b> , 1393-1404	
128	The Information Revolution Reaches Pharmaceuticals: Balancing Innovation Incentives, Cost, and Access in the Post-Genomics Era.	1
127	Hypothesis Generation: Asking the Right Question, Getting the Correct Answer. <b>2002</b> , 167-184	
126	Breast Cancer. <b>2002</b> , 345-365	1
125	Benchmarking in the ICU: The Measurement of Costs and Outcome to Analyze Efficiency and Efficacy. <b>2002</b> , 222-243	1
124	Cost-Effectiveness of Alternatives to Allogeneic Blood Transfusion; Reviewing the Available Evidence. <b>2002</b> , 131-142	
123	Disease management in chronic medical conditions. <b>2003</b> , 457-470	
122	Assessment of Outcomes in Head and Neck Cancer. <b>2003</b> , 433-444	
121	Issues in the Analysis of Cost-Effectiveness in the Diagnosis and Treatment of Coronary Artery Disease in Women. <b>2004</b> , 413-421	
120	Cost-effectiveness of primary prophylaxis for esophageal variceal bleeding. <b>2004</b> , 261-267	

- 119 COST-UTILITY ANALYSES IN ORTHOPAEDIC SURGERY. **2005**, 87, 1253-1259 1
- 118 Primary Prevention of Graves' Orbitopathy by Pentoxifylline (Randomized Controlled Trial). **2008**, 2, 603-613
- 117 Cost-Effectiveness of Endoscopic Therapy for Barrett's Esophagus. **2009**, 165-185
- 116 Cost-Effectiveness of Myocardial Perfusion Single-Photon Emission Computed Tomography. **2010**, 400-412
- 115 Outcomes Research. **2010**, 52-58
- 114 Modeling the Impact of Preventive Interventions on the National Homicide Rate. **2011**, 123-135 2
- 113 Pharmacoeconomics. **2011**, 1387-1392
- 112 Estandarizaci3n en el dise1o y realizaci3n de evaluaciones econ3micas: recomendaciones y gu1as existentes. **2012**, 21-36
- 111 Medical Economics in Interventional Cardiology. **2012**, 861-876
- 110 Tipos de costes a incluir en una evaluaci3n econ3mica. **2012**, 37-52
- 109 Gesundheitsbezogene Lebensqualit1t (HRQoL). **2013**, 161-178
- 108 Economic Analysis of Addiction Treatment Programs. **2013**, 599-609
- 107 The Health Implications of Disparities in Cancer and Pain Care: Unequal Burdens and Unheard Voices. **2014**, 1049-1054.e5
- 106 Medical Decision-Making Research in Surgery. **2014**, 195-204
- 105 Bibliograf1a. **2014**, 133-140
- 104 Economic Evaluation of Health Care for Chronic Diseases. **1998**, 149-154
- 103 Discourse on Method: Measuring the Value of New Therapies in Intensive Care. **1998**, 263-279
- 102 The Role of Cost-Effectiveness Analysis in Defining Transfusion Medicine Policy. **1999**, 47-57

101 Economic Perspectives on Intensive Care Medicine. **1999**, 669-678

100 Reporting Guidelines for Health Economic Evaluations: BMJ Guidelines for Authors and Peer Reviewers of Economic Submissions. 296-305

99 Important Research Principles in the Field of Spinal Osteotomy. **2015**, 269-277

98 Principles of health economics and application to rheumatic disorders. **2015**, 20-26

97 Clinical Decision Making. 639-650

96 Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework. **2016**, 16, 619-627

95 Identification of Chronic Wound Status under Tele-Wound Network through Smartphone. **2016**, 735-750

94 Cost-Effectiveness Analysis in Cancer Care. **2016**, 168, 377-91

0

93 From the Margins to the Mainstream. **2016**, 186-208

1

92 Reimbursement for Prostate Cancer Treatment. **2016**, 367-374

91 Establishing a Health Economic Evaluation for Collective Well-Being in Workplace Health Promotion. **2016**, 30, 5-8

90 Health-Related Quality of Life by Health States Related to Carotid Artery Stenosis in Korea. **2016**, 4, 23-29

89 Measuring Disease Activity and Outcomes in Clinical Trials. **2017**, 637-648

88 Economic Evaluations. **2017**, 409-426

87 Optimizing the Cost-Effectiveness of a Multicomponent Intervention Using Data from a Factorial Experiment: Considerations, Open Questions, and Tradeoffs Among Multiple Outcomes. **2018**, 207-267

1

86 From the Margins to the Mainstream. **2018**, 311-333

85 The History of Quality Assessment in Spine Care. **2019**, 29-49

84 Adherence to the iDSI reference case among published cost-per-DALY averted studies.

83	Financial Aspects of Inpatient Palliative Care. <b>2019</b> , 1783-1792	
82	Writing and Critically Appraising a Scientific Paper. <b>2019</b> , 247-260	
81	Health Economics: Tools to Measure and Maximize Programme Impact. <b>2019</b> , 363-382	
80	Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States.	
79	Economic Value in Spinal Tumor Surgery. <b>2020</b> , 203-209	
78	Incorporating future unrelated medical costs in cost-effectiveness analysis in China. <b>2021</b> , 6,	0
77	Analysis of EQ-5D Values. <b>2020</b> , 61-86	2
76	Decision Analysis and Cost-Effectiveness Research. <b>2020</b> , 229-236	
75	Identification of Chronic Wound Status under Tele-Wound Network through Smartphone. 991-1007	
74	Costs of providing HIV care and optimal allocation of HIV resources in Guyana. <b>2020</b> , 15, e0238499	1
73	Economics and Finance in Medical Quality Management. <b>2021</b> , 197-244	
72	Barriers and Facilitators to Implementation of a Preschool Outcome Measure: An Interview Study with Speech-Language Pathologists. <b>2021</b> , 95, 106166	0
71	A Systematic Review of Health State Utility Values in the Plastic Surgery Literature. <b>2021</b> , 9, e3944	0
70	Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States. <b>2021</b> , 1-9	
69	Long-Term Consequences of Major Extremity Trauma: A Pilot Study.. <b>2022</b> , 36, S21-S25	
68	Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life.. <b>2022</b> , 22, 46	1
67	Increasing HPV Vaccination Coverage on Preventing Oropharyngeal Cancer: A Cost-Effectiveness Analysis.. <b>2021</b> , 13, 200234	0
66	Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.. <b>2022</b> , 15, e007993	0

65	The cost-effectiveness of collegiate recovery programs.. <b>2022</b> , 1-12	
64	Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease.. <b>2022</b> , 1-29	2
63	Psychometric properties of the EQ-5D-3L in South Australia: a multi-method non-preference-based validation study.. <b>2022</b> , 1-30	1
62	Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China.. <b>2022</b> , 12, 4	
61	Quality, Safety, and Value Initiatives for Early-Onset Scoliosis. <b>2022</b> , 823-833	
60	Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer.. <b>2022</b> , 5, e2146312	0
59	Medical decision making. <b>2022</b> , 540-548	
58	Cost-Effectiveness of Early Intervention in Psychosis: A Modeling Study.. <b>2022</b> , appips202100161	0
57	Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea.. <b>2022</b> , 19,	
56	Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia.. <b>2022</b> ,	0
55	Exposure to Endocrine Disrupting Chemicals in Canada: Population-Based Estimates of Disease Burden and Economic Costs.. <b>2022</b> , 10,	2
54	The Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients (CLIP-OA) trial: Design and methods.. <b>2022</b> , 115, 106730	0
53	Understanding Health Economics in Joint Replacement Surgery.. <b>2022</b> , 1-10	
52	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.. <b>2021</b> , 12, 736860	0
51	Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time. <b>2021</b> , 40, 249	0
50	Evidence-based recommendations for economic evaluations in spine surgery: study protocol for a Delphi consensus.. <b>2021</b> , 11, e052988	0
49	Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.. <b>2021</b> ,	2
48	A cost-benefit analysis framework for preventive health interventions to aid decision-making in Australian governments.. <b>2021</b> , 19, 147	1



47	Personalized Medicine. <b>2022</b> , 13-80	
46	Patient-Reported Measures of the Effects of Vision Impairments and Low Vision Rehabilitation on Functioning in Daily Life.. <b>2022</b> ,	
45	How AI Can Help Depression Treatment. <b>2022</b> , 15-36	
44	Cost-effectiveness analysis of prosthesis provision for patients with transfemoral amputation in Tanzania.. <b>2022</b> ,	0
43	Using economic evaluations in implementation science to increase transparency in costs and outcomes for organizational decision-makers.. <b>2022</b> , 3, 40	1
42	Cost Effectiveness Analysis of Routine Use of Genotypic Antiretroviral Resistance Testing after Failure of Antiretroviral Treatment for HIV. <b>2004</b> , 9, 27-36	17
41	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. <b>2005</b> , 10, 41-52	8
40	Improving Early Infant Diagnosis for HIV-Exposed Infants Using Micro Unmanned Aerial Vehicles Versus Motorcycles for Blood Sample in Conakry, Guinea: A Comparative Cost-Effectiveness Analysis (ARNS 12407 AIRPOP).	
39	A Telehealth and Telepsychiatry Economic Cost Analysis Framework: Scoping Review.	2
38	The Optimal Length-of-Stay After Microvascular Breast Reconstruction: A Cost-Utility Analysis. Publish Ahead of Print,	
37	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. <b>2022</b> , 19, e1004032	1
36	A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. <b>2022</b> ,	0
35	Healthcare Resource Utilization and Cost Comparisons of High-Protein Enteral Nutrition Formulas Used in Critically Ill Patients. <b>2022</b> , 9, 1-10	
34	Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease. <b>2022</b> , 10, E923-E932	0
33	Healthcare Resource Utilization and Cost Comparisons of High-Protein Enteral Nutrition Formulas Used in Critically Ill Patients.	
32	COST-BENEFIT ANALYSIS FOR ALLERGEN IMMUNOTHERAPY. <b>2000</b> , 20, 593-607	
31	Antiseizure medication and perceived fair cost allocation: a factorial survey among neurologists, persons with epilepsy, their relatives and a control group.	
30	Cost-effectiveness analysis of radiosurgical capsulotomy versus treatment as usual for treatment-resistant obsessive-compulsive disorder. <b>2022</b> , 1-11	0

- 29 Economic Evaluation of Psychological Treatments for Common Mental Disorders in Low- and Middle-Income Countries: A Systematic Review.
- 28 The Cost Utility of Virtual Surgical Planning and Computer-Assisted Design/Computer-Assisted Manufacturing in Mandible Reconstruction Using the Free Fibula Osteocutaneous Flap.
- 27 The value of vaccines. **2022**, 78, 102243 ○
- 26 Tuberculosis in a weak health system, conflict and fragile zone: The monetary value of human lives lost associated with deaths of persons older than 14 years in Somalia. ○
- 25 Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China. ○
- 24 A systematic review of health state utility values in Thai cancer patients. 1-16 ○
- 23 Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis. **2022**, 11, ○
- 22 Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. ○
- 21 Cost-effectiveness analysis: percutaneous microwave ablation vs robotic-assisted partial nephrectomy for small renal masses. ○
- 20 Quality of Life and Related Outcomes Among Unpaid Caregivers of Older Adults With Visual Impairment. 009141502211321 ○
- 19 Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China. **2022**, 79, 2631-2641 ○
- 18 Antiretroviral therapy. **2023**, 263-283 ○
- 17 Despite Increasing Costs, Perfusion Machines Expand the Donor Pool of Livers and Could Save Lives. **2023**, 283, 42-51 ○
- 16 Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction. 1
- 15 Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population. ○
- 14 Cost Effectiveness of Universal Screening for Blunt Cerebrovascular Injury: A Markov Analysis. Publish Ahead of Print, ○
- 13 Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. Volume 16, 4273-4279 ○
- 12 Community Guide Methods for Systematic Reviews of Economic Evidence. **2022**, ○

- |    |   |   |
|----|---|---|
| 11 | Evaluation of Community-Based, Mobile HIV-Care, Peer-Delivered Linkage Case Management in Manzini Region, Eswatini. <b>2023</b> , 20, 38  | ○ |
| 10 | Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom. <b>2022</b> , 1-50     | ○ |
| 9  | Navigated intramedullary nailing for patients with intertrochanteric hip fractures is cost-effective at high-volume hospitals in mainland China: A markov decision analysis. 9, | ○ |
| 8  | Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. <b>2023</b> , 23, | ○ |
| 7  | Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. <b>2023</b> , 54, 407-414                 | 1 |
| 6  | Cost-Effectiveness of Smoking Cessation Interventions in Patients With Ischemic Stroke and Transient Ischemic Attack. <b>2023</b> , 54, 992-1000                                | ○ |
| 5  | Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis.   | ○ |
| 4  | Introduction to Cost-Effectiveness Analysis. <b>2013</b> , 1795-1801.e1   | ○ |
| 3  | Cost-effectiveness research. <b>2023</b> , 241-249  | ○ |
| 2  | Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India. <b>2022</b> , 156, 705                            | ○ |
| 1  | Normative profile of the EQ-5D-5L dimensions, EQ-5D-5L index and EQ-VAS scores for the general Thai population.   | ○ |